Calibration material delivery devices and methods

Information

  • Patent Grant
  • 11002743
  • Patent Number
    11,002,743
  • Date Filed
    Tuesday, February 13, 2018
    6 years ago
  • Date Issued
    Tuesday, May 11, 2021
    3 years ago
Abstract
A device includes: a first portion configured to be grasped by the hand of the user, and a second portion defining a reservoir containing a control material, wherein the control material contains a target analyte in a known or predetermined concentration. A method of verifying the accuracy of an analyte monitoring device includes receiving control information, receiving a fluid sample, identifying the fluid sample as a control solution, and analyzing the control solution.
Description
FIELD

The inventions described herein relates to devices and methods of delivering calibration or control information to a device, such as an analyte monitor.


BACKGROUND

In this specification where a document; act or item of knowledge is referred to or discussed, this reference or discussion is not an admission that the document, act or item of knowledge or any combination thereof was at the priority date, publicly available, known to the public, part of common general knowledge, or otherwise constitutes prior art under the applicable statutory provisions; or is known to be relevant to an attempt to solve any problem with which this specification is concerned.


Currently, analyte monitoring devices, such as blood glucose monitors, include a method of executing a “control fluid” test to determine if the device is functioning according to the manufacturer's expectations. Typically, users complete a “control” test by dispensing a variable amount of fluid onto a test strip from a vial packaged with the test kit. This vial contains a fluid within a known analyte concentration. After the users dispense the fluid onto the test strip the analyte monitor assumes the fluid is a body fluid and provides a result as usual. The device and/or the user can compare the concentration of target analyte measured by the device with the known concentration contained in the control solution as a measure of the accuracy of the monitoring device.


Current systems require the user to dispense the calibration fluid from a vial containing several doses of calibration fluid. When dispensing the fluid the user must take care not to spill the fluid on the device, or on the testing surface. Completing a control test also requires that users have the dexterity to deliver a small droplet of control solution from a vial onto the test strip; this is especially difficult when diseases such as diabetes affect the patient's vision and tactile sensation.


A typical calibration or control test requires the following steps:

    • 1. users find their control vial
    • 2. ensure that the control solution is still within its expiration limits
    • 3. find a test strip
    • 4. insert the test strip into the device or meter
    • 5. place the device into “control test mode” (if applicable)
    • 6. shake the bottle of solution
    • 7. open the control vial (using two-hands)
    • 8. carefully squeeze out enough control solution onto the test strip or the finger, taking care not to damage the analyte monitor by dispensing too much fluid
    • 9. accurately deliver the control solution to the analyte monitor
    • 10. compare the result of the control test versus the stated control range which may or may not be listed on the control vial
    • 11. mark the control test in their logbook so that health care professionals can remove this test from the users monthly averages if so desired.


Currently many users of analyte monitors find executing a control test to be a burdensome experience that they often ignore. By ignoring the control test users often will acquire erroneous information from their monitors, and this information may then be used to adjust drug treatments. The use of inaccurate information can lead to serious consequences, such as hypoglycemia in diabetes patients from a dosage of insulin that is too high.


While certain aspects of conventional technologies have been discussed to facilitate disclosure of the invention, Applicants in no way disclaim these technical aspects, and it is contemplated that the claimed invention may encompass or include one or more of the conventional technical aspects discussed herein.


SUMMARY

As used herein, “body fluid” encompasses whole blood, interstitial fluid, and mixtures thereof.


As used herein “integrated device” or “integrated meter” means a device or meter that includes all components necessary to perform sampling of body fluid, transport of body fluid, quantification of an analyte, and display of the amount of analyte contained in the sample of body fluid. Exemplary integrated meters are described in: U.S. Pat. Nos. 6,540,675 and 7,004,928; U.S. Patent Application Publication Nos. US 2008/0077048, US 2007/0179404, US 2007/0083131, US 2007/0179405, US 2007/0078358, and US 2007/0078313, The entire contents of each of the above-listed documents are incorporated herein by reference.


As used herein, “control material” means a material having a known and/or predetermined quantity or concentration of at least one, and possibly a plurality of, analyte(s) contained therein. The material can possess any suitable form. For example, the control material can be in the form of a liquid, a solid, a granular solid, a gas, a gel, a solution, a suspension, or any combination thereof. The analyte can comprise any suitable analyte. For example, the analyte can comprise one or more of: glucose, bilirubin, alcohol, controlled substances, toxins, hormones, and/or proteins.


It is to be understood that reference herein to first, second, third and fourth components (etc.) does not limit the present invention to embodiments where each of these components is physically separable from one another. For example, a single physical element of the invention may perform the functions of more than one of the claimed first, second, third or fourth components. Conversely, a plurality of separate physical elements working together may perform the functions of one of the claimed first, second, third or fourth components. Similarly, reference to first, second (etc.) method steps does not limit the invention to only separate steps. According to the invention, a single method step may satisfy multiple steps described herein. Conversely, a plurality of method steps could, in combination, constitute a single method step recited herein. In addition, the steps of the method are not necessarily limited to the order in which they are described or claimed herein.


It should also be understood that references herein to “the invention,” or similar language, is used to enhance readability and for convenience only, and should not be interpreted as a limitation on what is contemplated and comprehended by this disclosure and the appended claims. Instead “the invention” is intended to be interpreted as encompassing the full scope of what is claimed, regardless of the characterizations of the specific exemplary and non-limiting embodiments described in the specification.


The present invention may address one or more of the problems and deficiencies of the prior art discussed above. However, it is contemplated that the invention may prove useful in addressing other problems and deficiencies, or provides benefits and advantages, in a number of technical areas. Therefore the claimed invention should not necessarily be construed as being limited to addressing any of the particular problems or deficiencies discussed herein.


The invention can be useful with any device, but is particularly applicable to analyte monitors used in a home or clinical setting such as glucose monitors. The invention provides users of such monitors with a device that allows them to quickly and easily deliver one or more doses of calibration or control information to one or more devices, such as an analyte monitor. The invention also provides for mechanisms and methods that can automatically differentiate a calibration test from a typical test. This invention is aimed at devices requiring calibration or the ability to execute a control test. For example, in the case of analyte monitors where an analyte of a known concentration is delivered to the analyte monitor to ensure that it is functioning properly. According to the principles of the present invention, a typical user can easily and quickly execute a proper calibration test to ensure device functionality without assistance from a trained health care professional. Alternatively, the present invention can also be utilized by medical professionals in a clinical setting.


The invention can be used with an integrated device or integrated meter of the type defined above. However, the invention is not limited to use with fully integrated meters, and benefits can also be attained by use with conventional (non-integrated) meters and other diagnostic devices where collection of accurate data and analysis of data is important.


The invention can provide a device containing a single dosage, or multiple doses of control material in a convenient easy-to-use package. The control material can be contained within an applicator that is large enough for easy handling and sealed according to a number of alternative ways so that the risk of spillage or damage to the analyte monitor is greatly reduced.


This device simplifies a control test and encourages users to perform a control test more often so that any problems with their analyte monitors can be found more quickly.


The invention can provide for use of one or more dosage(s) of a predefined volume of control material, thereby ensuring more accurate data by allowing users to deliver the required amount of control solution, unlike previous methods in which it is quite possible that users could deliver too much or too little control solution. As previously mentioned, by sealing each dosage individually the viability of the control sample can be enhanced and users are less likely to use expired control material. The accuracy of the average data stored within the analyte monitor can also be increased by automatically marking or differentiating a control test from a normal or actual test so that the control test value can not impact the averages of normal analyte testing (weekly, monthly, etc) stored within the unit.


According to certain aspects, the invention provides mechanisms and methods that can determine automatically if the sampled material is body fluid or control material without the user's intervention. Also, the individual packaging of each control test ensures that each solution dosage will remain enclosed in a protective environment and allows for an extended expiration date.


According to a first aspect, the present invention provides a device comprising: a first portion configured to be grasped by the hand of the user; and a second portion defining a reservoir containing a first control material, wherein the control material comprises a target analyte of a known or predetermined concentration.


According to another aspect, the present invention provides In combination, an integrated meter comprising a housing with an opening formed therein, and the device as described above, the second portion comprising a body and a flange shaped and configured to be received by the integrated meter.


According to an additional aspect, the present invention provides a method of conveying a control material to an analyte monitor, the method comprising: (i) providing a dispenser comprising a first portion configured to be grasped by the hand of the user, and a second portion defining a reservoir having a frangible seal thereon, the reservoir containing a control material, wherein the control material contains a target analyte in a known and/or predetermined concentration; (ii) breaking the frangible seal; and (iii) conveying the control material to a location for analysis by the analyte monitor.


According to another aspect, the present invention provides a method of verifying the accuracy of the operation of an analyte monitoring device using a control material having a known and/or predetermined concentration of at least one analyte, the method comprising: providing a single or multi-test cartridge having information associated therewith defining an acceptable range of measured analyte concentration values for the control material; associating the single or multi-test cartridge with the device; reading the information off the single or multi-test cartridge; introducing a control material to the single or multi-test cartridge; the device automatically determining the presence of a control material; analyzing the control material to measure the concentration of analyte contained therein; and comparing the measured concentration with the control information to determine if the measured concentration corresponds to the acceptable range of concentration values obtained from the information.





BRIEF DESCRIPTION OF THE DRAWING FIGURES

The following description of exemplary embodiments can be read in connection with the accompanying drawings in which like numerals designate like elements and in which:



FIG. 1 is a side view of a device formed according to one embodiment of the present invention.



FIG. 2 is a sectional view taken at line A-A of FIG. 1.



FIG. 3 is a bottom view of the device of FIG. 1.



FIG. 4 is a schematic illustration of a device and a possible implementation, use or method involving the device, according to further alternative embodiments.



FIG. 5 is a side view of a device formed according to an additional alternative embodiment of the present invention,



FIG. 6 is a sectional view taken at line A-A of FIG. 5.



FIG. 7 is a perspective view of the device of FIG. 5.



FIG. 8 is an exploded perspective view of the device of FIG. 5.



FIG. 9 is a perspective view of a device formed according to another embodiment of the present invention.



FIG. 10 is a perspective view of one of the individual devices of FIG. 9.



FIG. 11 is a top view of one of the individual devices of FIG. 9.



FIG. 12 is a side view of one of the individual devices of FIG. 9.



FIG. 13 is a bottom view of one of the individual devices of FIG. 9.



FIG. 14 is a side view of a device formed according to a further embodiment of the invention.



FIG. 15 is an edge view of the device of FIG. 14.



FIG. 16 is a longitudinal sectional view of the device of FIG. 14.



FIG. 17 is an exploded view of the device of FIG. 14.



FIG. 18 is a longitudinal sectional view of an alternative embodiment of a device according to the present invention.



FIG. 19 is a side view of a further alternative embodiment of a device formed according to the present invention.



FIG. 20 is a longitudinal sectional view of the device of FIG. 19.



FIG. 21 is a longitudinal sectional view of an additional alternative embodiment of a device of the present invention in a first state.



FIG. 22 is a longitudinal sectional view of the device of FIG. 20, in a second state.



FIG. 23 is a side view of a yet another embodiment of a device formed according to the invention.



FIG. 24 is a longitudinal sectional view of the device of FIG. 23.



FIG. 25 is a sectional view of a further alternative embodiment of a device of the present invention.



FIG. 26 is an enlargement of the detail of area B in FIG. 25.



FIG. 27 is a schematic illustration of certain techniques and mechanisms for providing calibration information.



FIGS. 28A-28D illustrate a method and possible uses of a device according to further alternative embodiments of the present invention.



FIGS. 29A-29D illustrate an alternative method and possible uses of a device according to additional alternative embodiments of the present invention.



FIGS. 30A-30B illustrate an additional alternative method and possible uses of a device according to further alternative embodiments of the present invention.





DETAILED DESCRIPTION

In general terms this invention describes a device that allows a user to deliver a one or more doses of control material, such as a control fluid or control solution, to one or more devices such as a meter or monitor, for example, an integrated blood glucose monitor previously described herein. The method of and apparatus for delivery of the control solution can take many forms, such as a prepackaged “blister” of control solution or a “wand,” with a known predetermined volume of control solution available for delivery to the analyte monitor. Exemplary, non-limiting embodiments of the present invention are illustrated in Figures which follow.


As illustrated in FIGS. 1-4, a device 10 constructed according to a first illustrated embodiment comprises two portions; a first portion 12 and a second portion 14. The first portion 12 serves primarily as a handle for manipulation of the device 10 by a user. Thus, the first portion 12 can be provided with any suitable form which provides the desired functionality. Therefore, it should be evident that the form of the first portion 12 is not limited to the illustrated embodiment. According to the non-limiting illustrated embodiment, the first portion 12 is in the form of an elongated cylindrical body.


The second portion 14 provides a mechanism for carrying a control or calibration material, as well as optionally mating with a meter or monitor (see, e.g. FIG. 4). Thus, the second portion 14 can have any suitable form that provides this functionality. According to the nonlimiting illustrated embodiment, the second portion 14 defines a reservoir 16. The reservoir 16 can have any suitable form, and is not limited to the form shown in the illustrated embodiment. The reservoir contains a control material. Any suitable control material can be utilized. The control material comprises a target analyte, such as glucose, in a known and/or predetermined concentration, Optionally, the control material may contain a plurality of target analytes. According to one alternative embodiment, the control material is in the form of a control liquid or solution. According to a further alternative embodiment, the control material is in the form of a liquid or solution that is carried by an absorbent or porous material, such as a sponge-like material. Thus, according to the one optional embodiment, the control material 18 is in the form of an absorbent or porous material having a control liquid, suspension or solution absorbed therein.


The reservoir 16 containing the control material 18 can be provided with a closure or seal 20. The closure or seal 20 acts to contain the control material 18 within the reservoir 16, and to prevent contamination by shielding the control material 18 from the environment. The closure or seal 20 can be provided in any suitable form, and can be constructed of any suitable material. According to one non-limiting example, the closure or seal 20 can be in the form of a thin, frangible, closure, such as a metallic foil.


As noted above, according to one optional embodiment, the second portion 14 serves to mate with an analyte monitor such that the control material 18 can be dispensed. Thus, the second portion can be provided with a shape and size that renders it suitable for mating with a meter or monitor. It should be evident that the construction of the particular device with which the second portion 14 will mate can influence both the size and shape of the second portion 14. According to the nonlimiting illustrated example, the second portion 14 comprises a flanged 22 cylindrical body 24, as perhaps best seen in FIG. 3, which is dimensioned to mate with an opening formed in an analyte monitor, as best illustrated in FIG. 4. Thus, according to one possible implementation or embodiment of the present invention, an opening is formed in an analyte monitor by a flexible footprint or interface device 26 which is mounted to the housing 28 of the meter or monitor. The body 24 of the second portion 14 of the device 10 is inserted into the opening to a desired depth, which is controlled or defined by the location of the flange 22. According to one non-limiting example, the analyte monitor includes a piercing element, or hollow needle, 30 which can be actuated such that it breaks the seal 20 and comes into fluid communication with the control material 18. The hollow piercing element 30 then transports the control material 18 into the analyte monitor, as indicated by the arrow appearing in FIG. 4, wherein the monitor includes an appropriate mechanism for analyzing the control material to measure the concentration of the target analyte(s) contained therein. Such mechanisms may include electrochemical or colorimetric analysis, as described in connection with the description of the integrated meters previously referenced herein.


A device constructed according to further alternative embodiments of the present invention is depicted in FIGS. 5-8. The device has a construction and functionality which is similar to that of the previously described embodiments. Therefore, where a feature of the alternative embodiments finds a corresponding feature with the previously described embodiments, they have been given similar reference numeral (e.g., 12 and 112). Therefore, reference is made to the previously described embodiments for a full description of these corresponding features.


As illustrated in FIGS. 5-8, the first portion 112 of the device 100 is provided with a configuration which facilitates handling by a user. This is particularly important when the device 100 is intended for use with blood glucose monitors. This is because people with diabetes can lack tactile dexterity. Thus, the first portion 112 of the device 100 can be provided with any suitable form which facilitates grasp by a user.


According to the illustrated embodiment, the first portion 112 comprises a flattened relatively wide paddle-like shape. The paddle-like shape includes facing surfaces 113 which are contoured in an hourglass type manner such that the second portion 112 is provided with a cross-section that is relatively thin toward the middle, and wider towards its ends (FIG. 6). The second portion 112 may optionally be provided with a feature that reduces slippage. For example, according to the nonlimiting illustrated embodiment, the second portion 112 is provided with a series of raised projections or ribs 115, Alternative features, such as a high friction surface coating or material disposed on all or a portion of surfaces 113 and/or ribs 115 may also be provided.


The second portion 114 of the device 100 defines a reservoir 116, which houses a control material 118, which can take any suitable form, such as that described in connection with the previous embodiments. The reservoir 116 can be sealed by a corresponding closure or seal 120. The second portion 114 further comprises a flanged 122 body 124, configured in a manner similar to that of the previously described embodiment.


In the embodiments depicted in FIGS. 5-8, the first portion 112 in the second portion 114 are formed as separate components which are assembled together and secured in any suitable fashion, such as by adhesive or a fastener. However, it should be understood that the invention is not so limited. Namely, the device 100 can have an integral or single-piece monolithic construction.


It should be evident that the device 100 has a configuration such that it can be utilized in a manner similar to that of the previous embodiment, as depicted in FIG. 4 herein.


The device of the present invention, and components thereof, can be made of any suitable material, such as, metal, wood, plastic, etc. In a preferred embodiment, the device can be made of an injection molded plastic material to simplify production and reduce costs. Similarly, in one optional embodiment, a control solution is absorbed onto a carrier layer of porous absorbent material that is placed into a reservoir in the control wand then sealed with a frangible environmental seal, such as a thin aluminum foil. It is also understood that the control material could be placed directly into the cavity in the control wand and sealed without a carrier. Instead of a wand-type delivery device of the type previously described, the control material delivery device could come in the form of a:

    • blister filled with control material. The foil sealed blister could still be used to initiate the test as described herein
    • gel-cap filled with control material similar to gel-caps used to delivery drugs such as OTC pain reducers, or
    • any other method of containing and automatically dispensing an appropriate dosage of control material.


An example of the above-mentioned alternative control material delivery devices is illustrated in FIGS. 9-13. This illustrated therein, a plurality of such devices 150 can be coupled or packaged together. Each individual control material delivery device 152 is separable by any suitable mechanism. For instance, the plurality of devices 150 can be provided with frangible areas 154 for separating the individual devices 152 from one another. The frangible areas 154 can be provided by any suitable mechanism, such as scoring or other weakening of the material in these areas.


Each individual control material delivery device 152 can be provided in any suitable form. According to the illustrated embodiment, each device 152 can comprise a body 156. The body 156 can take any suitable form. According to the illustrated embodiment, the body 156 is in the form of a strip-like member. The body 156 can be formed from any suitable material, such as a plastic, fibrous material, or composite.


Attached to the body 156 is a reservoir 158. The reservoir can be provided with any suitable construction. For example, the reservoir can be configured to mate with an opening provided in an analyte monitor or meter, for example, in the manner previously described in connection with the description of FIG. 4. Each reservoir 158 is configured to receive a control material 160 therein. Each reservoir 158 may also be provided with a seal 162 to maintain that control material 160 within the reservoir 158. The seal 162 can take any suitable form. For example, the seal 162, according to the illustrated embodiment, comprises a pierceable member such as a thin metal foil. Thus, the seal 162 may optionally be provided with a construction which is pierceable by a member such as a hollow needle, as previously described in connection with the embodiment depicted in FIG. 4. Each device 152 may also be provided with a flange-like member 164 which is also attached to the body 156 of the device 152. The flange-like member 164 provides rigidity and support to the reservoir 158, and facilitates attachment thereof to the body 156.


The flange-like member 164 may also include a backing 166 which is not pierceable. Thus, for example, the backing 166 is not pierceable by a hollow needle. This construction of the backing 166 can be provided to protect the fingers of a user when the reservoir 158 is inserted into a meter or monitor, which includes a piercing element, such as a hollow needle, which is used to access the control material 160 within the reservoir 158.


Devices constructed according to further alternative embodiments of the present invention are depicted in FIGS. 14-30B. These devices have a construction and functionality which is similar to that of the previously described embodiments. Therefore, where a feature of the alternative embodiments finds a corresponding or feature in common with the previously described embodiments, they have been given similar reference numerals (e.g., 113 and 213). Therefore, reference is made to the previously described embodiments for supplemental description of these previously described features.


The devices and methods according to the embodiments depicted in FIGS. 14-30B have certain features in common. For instance, according to these alternative embodiments, the device 200 can possess a single piece construction, as opposed to a two-piece construction described according to other embodiment of the present invention. Each of these embodiments also may possess a reservoir constructed to retain a control material in flowable or liquid form, the provision of a porous or absorbent material as a carrier is not required, however, may be present according to further optional embodiments. These embodiments also possess a flexible neck construction which facilitates alignment and usage of the device, in particular by people with diabetes. The devices of these embodiments can also be made of any suitable material, such as, metal, wood, plastic, etc. According to one option, the device can be made of an injection molded plastic material to simplify production and reduce costs.


As illustrated, for example, in FIGS. 14-17, the first portion 212 of the device 200 is provided with a configuration which facilitates handling by a user. This is particularly important when the device 200 is intended for use with blood glucose monitors. This is because people with diabetes can lack tactile dexterity, Thus, the first portion 212 of the device 200 can be provided with any suitable form which facilitates grasp by a user.


According to the illustrated embodiment, the first portion 212 comprises a flattened relatively wide paddle-like shape. The paddle-like shape includes facing surfaces 213 which are contoured in an hourglass type manner such that the second portion 212 is provided with a cross-section that is relatively thin toward the middle, and wider towards its ends (FIGS. 15-16). The first portion 212 may optionally be provided with a feature that reduces slippage. For example, according to the nonlimiting illustrated embodiment, the first portion 212 is provided with a series of raised projections or ribs 215, Alternative features, such as a high friction surface coating or material disposed on all or a portion of surfaces 213 and/or ribs 215 may also be provided.


The device 200 may further include a second portion 214 with a flexible neck construction 230. The flexible neck 230 facilitates usage of the device by permitting relative movement between the first portion 212 and second portion 214 of the device. The flexible neck 230 can facilitate use of the device 200 in connection with mating the body 224 with an opening in a meter. The relative movement between the first portion 212 and the second portion 214 facilitates keeping the flanged 222 body 224 pressed flat against the opening, thus improving the ability to form a seal therewith. The flexible neck 230 may possess any suitable construction permits this desired relative movement. Thus, the flexible neck may simply comprise a relatively thin neck of flexible material, or other alternative configurations. According to the illustrated examples, the flexible neck 230 comprises a series of sections 231 interconnected by one or more thin flexible necks 232.


The second portion 214 of the device 200 can define a reservoir 216, which houses a control material 218, as described in connection with the previous embodiments, Optionally, the control material 218 can contain one or more target analytes having a known and/or predetermined concentration and can be in liquid or flowable form as illustrated in, for example, FIGS. 16-17. The reservoir 216 can be sealed by a corresponding closure or seal 220. The second portion 214 further comprises a flanged 222 body 224, configured in a manner similar to that of the previously described embodiment.


According to certain alternative embodiments, the device 200 can include one or more features which allow the user to urge the control material out of the device so as to deliver it to its intended location. A number of such features are contemplated, including the use of positive and/or negative pressures. According to one nonlimiting, specific example, as illustrated in FIG. 18, the first portion 212 of the device 200 can comprise a hollow interior region 260. Further, the second portion 214 of the device may also comprise a hollow region 262, which is preferably in communication with the first hollow region 260. Thus, the user is able to grasp the handle 213 and squeeze in the direction of the horizontal arrows appearing in FIG. 18. This compression of hollow region 260 forces any air, or other fluid, contained therein in the direction of the vertical arrow. The forced fluid then travels through the second hollow region 262 and into the reservoir 216, where it then acts to force the control material 218 out the opening of the reservoir 216. It should be evident that any of the previously or subsequently described embodiments can be modified in a suitable manner, similar to that described above, to provide the same optional functionality.


As mentioned above, in the embodiments depicted in FIGS. 14-24 the first portion 212 in the second portion 214 are integrally formed or comprise a single-piece monolithic construction. However, the invention is not so limited and can be formed in multiple parts that are either permanently or releasably connected together.


It should be evident that the device 200 has a configuration such that it can be utilized in a manner similar to that described in connection with the previous embodiments.


The device 200 illustrated in FIGS. 19-20 has the same features as the device 200 described above. As illustrated in FIGS. 19-20, the device 200 according to this alternative embodiment possesses a gasket or seal 240 disposed about the body 224 and abutting the flange 222. The gasket 240 can be formed from any suitable material, natural or synthetic. For example, the gasket 240 can be formed from foam, rubber, cork material, or a composite. The gasket 240 can be a separate component that is fitted over the body. When formed as a separate component, the gasket can be held in place by friction or by a suitable adhesive. Alternatively, the gasket 240 can be co-molded with the device 200 so as to be unified therewith. The gasket 240 enhances a seal formed between the flanged 222 body 224 when the device 200 is used in conjunction and mated with an opening of a meter, as will be described in greater detail herein.


The device 200 illustrated in FIGS. 21-22 has the same features as the device 200 described above. As illustrated in FIGS. 21-22, the device 200 according to this alternative embodiment possesses an alternative closure 250 for the reservoir 216. The alternative closure 250 can have any suitable construction. According to the optional illustrated embodiment the closure 250 comprises a handle or hinge 252 connected to the flanged 222 body 224. The hinge 252 can be connected in any suitable fashion. According to the illustrated embodiment, the hinge 252 is integrally formed with the flanged 222 body 224, such as by molding. Alternatively, the hinge may be separately formed and secured in place by adhesive, heat welding, ultrasonic welding or other suitable technique. The hinge may also include a ring or collar that fits around the body 224 to secure the hinge 252 in place. The closure 250 may further include a cap portion 254 that mates with reservoir 216 opening forming a seal therewith to contain the control material 218 contained therein (FIG. 16). According to one optional embodiment, the cap portion 254 can be pressed down and lifted up by a user to form a re-sealable closure. Alternatively, the cap portion 254 can be secured in place to the flanged 222 body 224 by adhesive, heat welding, ultrasonic welding, or other suitable technique. The cap portion may comprise a frangible portion 256. The frangible portion 256 can be constructed so that it is pierceable by a lancet, needle, or similar modality.


The device 200′ illustrated in FIGS. 23-24 can share any combination or all of the same features as the device 200 of the previously described embodiments. The main distinction is that device 200′ has two second portions 214A, 214B, each with a flexible neck construction 230A, 230B optionally provided with a construction previously described herein (components of the second portion 214A are labeled as in previous figures with “A” added to each label, and the components of the second portion 214B are labeled as in previous figures with “B” added to each label). Each second portion 214A, 214B of the device 200′ defines a reservoir 216A, 216B which houses a control material 218A, 218B. The control material 218A, 218B can be essentially the same, thus providing the ability to perform at least two similar control tests with the same device 220′. As previously described, the control material may contain one or more target analyte(s). Alternatively, the control material 218A can differ from the control material 218B in one or more respects. For example, the first control material may contain a relatively lower concentration of a target analyte, while the second control material may contain a relatively higher concentration of the target analyte, thus providing a single device 200′ with the ability to conduct a control test for both low and high analyte concentration ranges to ensure even greater accuracy of a meter or other measuring device. According to a further option, the control materials 218A, 218B can be used to perform a control test for at least two different target analytes. Thus, the first control material 218A can have a known concentration of a first analyte, while the second control material 218B can have a known concentration of a second analyte. The reservoirs 216A, 216B can be sealed by a corresponding closure or seal 220A, 220B, as illustrated. Alternatively, the closure can be constructed as illustrated and described above in connection with FIGS. 21-22. The second portions 214A, 214B can have either the same type of closure or seal, or different types of closures/seals.


According to further optional embodiments of the present invention, any of the previously or subsequently described embodiments can be modified so as to include an alternative reservoir construction, an example of which being illustrated in the embodiments depicted in FIGS. 25-26. As illustrated therein, the second portion 214 of the device includes a modified reservoir 216′. The modified reservoir 216′ can be generally characterized as being in the form of a separable multi-piece construction. Such a construction can provide certain advantages. For example, the separable reservoir component containing the control material can be in the form of a cartridge which can be inserted into a reusable handle portion constituting the remainder of the device, Thus, once the control test has been conducted, the separable reservoir component containing control material can be removed and discarded appropriately. Such a construction may provide advantages in terms of cost and convenience, as well as significantly reducing waste due to the reusability of the handle portion. Further, the separable reservoir component containing the control material can be formed of a material which is different in nature than that of the handle portion into which it is inserted. For instance, the separable reservoir component can be formed from a relatively low moisture vapor transmission rate (LMVTR) material. Thus, the control material is kept in a more stable manner that would be possible using a higher moisture vapor transmission rate material. To the extent that the LMVTR material is more costly than a relatively higher moisture vapor transmission rate material, cost savings can be obtained through the above-mentioned modified reservoir construction.


The above noted concepts can be executed in any suitable manner, According to the nonlimiting illustrated embodiment, the modified reservoir portion 216′ comprises a lower member 270 defining a recess 272 therein. Received within a recess 272 is a separable reservoir component 274 containing the control material 218. The separable component may be closed by a frangible seal 220, as previously described. As noted above, this separable component 274 can be formed of any suitable material, such as a LMVTR plastic material. The separable component 274 can be retained within the recess 272 in any suitable fashion, Contemplated alternatives include adhesives, fasteners, and frictional retention. According to the illustrated embodiments, the separable component 274 is retained within the recess 272 by plurality of interacting frictional detents 276, 278.


Further aspects of the invention involves analyte testing/monitoring devices and methods including the devices (e.g., 100, 200, 200′) of the type described above in conjunction with an integrated analyte monitor or meter. The integrated monitor or meter optionally being capable of one or more of the following:

    • extracting the control material
    • transporting the control material to an analysis site within the integrated monitor (e.g., as described in several of the integrated meter documents incorporated herein by reference)
    • analyzing the control material to determine the concentration of the analyte contained in the fluid
    • analyzing the control to determine whether the sample is a body fluid or a control material
    • comparing the result of the control test against a control calibration value, which may be read off a barcode, RFID, or similar device and/or stored in a memory of the monitor or meter, and
    • displaying the result of the control test as a simple-to-interpret pass or fail result through simple audible/visual signals.


To complete the described steps automatically the analyte monitor should also have the capability of gathering calibration information automatically, such as from an analyte concentration measuring and analysis mechanism contained with the device. If analysis site(s) is/are contained within a single strip or multi-test cartridge CR, as illustrated in FIG. 27, the calibration information for the analyte concentration measuring and analysis mechanism(s) could be delivered to the meter or monitor M via a bar code BR, RFID chip CH or other mechanism.


One advantage of the invention is automated detection and marking of a control test to distinguish that test from, for example, a test involving a sample of body fluid. This can be accomplished by several methods; one method of identifying a control test is described as follows. The control material can be designed such that it reacts with the analysis site in a manner distinguishable from the reaction with a bodily fluid. For example, the viscosity of the control material can be so different, either lower or higher than the tested body fluid, that the rate of reaction or sample delivery can be used to distinguish control material from body fluid. Specifically, glucose monitors typically have stated hematocrit ranges that are acceptable for use with the device. As hematocrit increases the viscosity of blood also increases. The analysis site and method could be designed in such a manner that the rate of reaction is inversely related to hematocrit (higher hematocrit=slower reaction). This has been described, for example, in US 2006/0281187, the entire contents of which is incorporated herein by reference. To accomplish this, the control material used within the analysis site could be contained in a porous material. The size of the pores in the material can be used to control the rate of reaction. The control fluid can be designed such that its viscosity is lower than the equivalent viscosity of the lowest allowable hematocrit level. Therefore as the analysis is completed within the integrated monitor the rate of reaction can be used to identify control material tests.


Another method of identifying a control sample versus a body fluid sample involves adding identifying markers to the control material. For example, control material could be identified by optical detection by adding color within the detection wavelength such that a color change of an order of magnitude higher than physiologically possible given the kinetics of the assay occurs nearly instantaneously. The degree of color added via a dye or other colored means is enough to detect via this method, but not so much as to reduce the dynamic detection range of the system so that the proper level of analyte detection in the control material can correctly indicate system analyte recovery status as “Pass” or “Fail” through clear audible and/or visual signals. Another similar option that may be implemented is to provide the control material with a chemical marker that initially reacts with the analysis site to produce an initial spike in color indicating to the meter the presence of control solution. The initial color spike can be designed to quickly disappear. Subsequently, the analysis site reacts with the analyte(s) in a manner that can be read and interpreted to determine the concentration thereof.


Other similar methods of observing the time rate of change of the analysis site (reagent) are also comprehended, i.e., very slow reaction, or reactions proceeding along known value vs. time plots, etc.


According to further alternative embodiments, the automated determination of a control solution test can be accomplished using algorithms executed by the electronic components within a monitor or meter.


A method performed according to the principles of one embodiment of the present invention includes one or more of the steps in FIGS. 27 and 28A-28D:\


Step 1: Provide calibration information to the monitor or device (e.g., FIG. 27 as described above).


Step 2: Use control material applicator (100, 200, 200′) to deliver a dose of control material to monitor or device (M) (FIG. 28A). Note: The integrated monitor can optionally detect the presence of a “finger,” in this case the control wand (100, 200. 200′), and automatically lances the closure (20, 120, 220, 256) and transports the control material (18, 118, 218) (e.g., FIG. 4).


Step 3: Integrated monitor analyzes the control material and determines that sample is a control test as indicated by any suitable symbol, such as the “check-mark” symbol on LCD (FIG. 28B). Alternatively, the monitor may provide an audible signal in place of, or in addition to, the symbol.


Step 4a: Control material is analyzed and its analyte concentration value is displayed (e.g., 100 mg/dL) and compared against stored calibration values. In this example, the value is within the expected range and device displays any suitable symbol (280C), such as the “check” indicating “pass” (FIG. 28C). Alternatively, the monitor may provide an audible signal in place of, or in addition to, the symbol.


Step 4b: Control material is analyzed, the measured analyte concentration displayed and found to be outside of the expected range. In this case, the monitor indicates a failed test by displaying any suitable symbol (280D), such as crossed-out check mark. Alternatively, the monitor may provide an audible signal in place of, or in addition to, the symbol. Note the “i” symbol indicates that user should look at manual to see how to address the failed test (FIG. 28D).


An alternative method performed according to a further optional embodiment is illustrated in FIGS. 27 and 29A-29D, and is described as follows.


Step 1: Provide calibration information to the monitor or device (e.g., FIG. 27 as described above).


Step 2: Use control material applicator (100, 200, 200′) to deliver a dose of control material (18, 118, 218) to monitor or device (M) (FIG. 29A). Note: The integrated monitor can optionally detect the presence of a “finger,” in this case the control wand (100, 200, 200′), and automatically lances the closure (20, 120, 220, 256) and transports the control material (e.g., FIG. 4). The monitor M can optionally signal the user when the applicator can be removed from the opening.


Step 3: Integrated monitor analyzes the control material and determines that sample is a control test as indicated by any suitable symbol, such as the “check-mark” symbol on LCD (e.g., FIG. 29B). Alternatively, the monitor may provide an audible signal in place of, or in addition to, the symbol.


Step 4a: Control material is analyzed and its analyte concentration value is compared against stored calibration values. In this example, the value is within the expected range and device displays any suitable symbol, such as the “check” and a “P” indicating “pass” (FIG. 29C). Alternatively, the monitor may provide an audible signal in place of, or in addition to, the symbol. Additional and/or alternative visual and audible signals are contemplated. For example, the meter M can play a recorded spoken “pass” message. Note that unlike the previous embodiment, the concentration of analyte measured by the device is not displayed. It has been found that some users can become confused by the display of a concentration value and mistakenly assume it is a reading of the concentration of analyte in a sample of the user's body fluid, and engage in treatment (e.g., insulin dosage) based on this misunderstanding of the concentration value displayed by the meter M. This embodiment avoids such opportunity for misinterpretation.


Step 4b: Control material is analyzed, the measured analyte concentration value is compared by the meter M against stored control or calibration values and found to be outside of the expected range. In this case the monitor displays a fail test. Any suitable symbol, such as the symbol indicated by the crossed check mark and “F,” indicative of a failed control test. Additional and/or alternative visual and audible signals are contemplated. For example, the meter M can play a recorded spoken “fail” message. Note the “i” symbol indicates that user should look at manual to see how to address the failed test (FIG. 29D).


It should be understood that the present invention is not limited to use of the devices (100, 200, 200′) described herein with a particular type of meter or device. The present invention contemplates devices and methods that do not rely upon an integrated type meter or monitor. For example, many commercially available blood glucose monitoring systems include a lancing device, test strips and meter, one or more of which are separate components of the system. An arrangement and a control testing method performed according to an alternative embodiment of the present invention is illustrated in FIGS. 30A-30B. As illustrated therein, a device of the type described herein (100, 200, 200′) contains a control material C. The control material C can have any suitable form or composition as previously described herein (18, 118, 218). The control material C is accessed by any suitable measure, such as by using a separate lancing device L that is commonly part of non-integrated blood glucose monitoring systems to pierce the closure or seal of the reservoir containing the control material C (FIG. 30A). A test strip S used for analyzing the concentration of a target analyte in a sample of body fluid by know techniques is inserted into a non-integrated meter M2. Using the device (100, 200, 200′) the control material C is applied to a test strip S in a manner similar to how the user would introduce a sample of body fluid, such as blood obtained from a finger prick. The control material is then analyzed by the strip S and meter M2 in any suitable manner in order to verify whether or not the measured concentration of analyte in the control material C is within a tolerable expected range, and the results presented to the user. This can be done in any suitable manner, such as described herein in connection with previous embodiments.


According to one optional modification of the above described embodiment of FIGS. 30A-30B, instead of using the device (100, 200, 200′) to apply the control material C directly to the test strip S, the control may be applied directly to the surface of a finger. The test strips is then brought into communication with the control material C on the finger, and is transported therein for analysis. This procedure more closely mimics a finger prick test using such non-integrated mete and thus may be easier for the user to practice due to the familiarity of steps.


Numbers expressing quantities of ingredients, constituents, reaction conditions, and so forth used in this specification are to be understood as being modified in all instances by the term “about”. Notwithstanding that the numerical ranges and parameters setting forth, the broad scope of the subject matter presented herein are approximations, the numerical values set forth are indicated as precisely as possible. Any numerical value, however, may inherently contain certain errors necessarily resulting from the standard deviation found in their respective measurement techniques. None of the elements recited in the appended claims should be interpreted as invoking 35 U.S.C. § 112, ¶6, unless the term “means” is explicitly used.


Although the present invention has been described in connection with preferred embodiments thereof, it will be appreciated by those skilled in the art that additions, deletions, modifications, and substitutions not specifically described may be made without departing from the spirit and scope of the invention as defined in the appended claims.

Claims
  • 1. A method of verifying the accuracy of an analyte monitoring device through a control test, the method comprising: receiving control information with the analyte monitoring device, wherein the control information comprises a range of analyte concentration values for a control solution;receiving a fluid sample with the analyte monitoring device;identifying the fluid sample as the control solution with the analyte monitoring device automatically, wherein the control solution has a known and/or predetermined concentration of at least one analyte;analyzing the control solution to measure the concentration of the at least one analyte contained therein;comparing the measured concentration of the at least one analyte in the control solution with the control information; andproviding a signal to indicate whether the measured concentration falls within the range of analyte concentration values.
  • 2. The method of claim 1 further comprising detecting the presence of a control solution device with the analyte monitoring device.
  • 3. The method of claim 1 further comprising lancing a control solution device with the analyte monitoring device to extract the control solution therein.
  • 4. The method of claim 1 wherein identifying the fluid sample as the control solution comprises analyzing the fluid sample using a colorimetric technique.
  • 5. The method of claim 1 wherein identifying the fluid sample as the control solution comprises analyzing the rate of reaction of the fluid sample.
  • 6. The method of claim 1 wherein identifying the fluid sample as the control solution comprises analyzing the wavelength of the fluid sample.
  • 7. The method of claim 1 wherein the at least one analyte comprises glucose.
  • 8. The method of claim 1 wherein the control information is received from a test cartridge.
  • 9. The method of claim 8 wherein the test cartridge comprises a multi-test cartridge.
  • 10. The method of claim 8 wherein the control information is contained in a barcode or RFID chip associated with the test cartridge.
  • 11. The method of claim 1 wherein the fluid sample is received by an analysis site that comprises a reagent.
  • 12. The method of claim 1 wherein the signal is a pass signal or a fail signal.
  • 13. A system for verifying the accuracy of an analyte monitoring device through a control test, the system comprising: an analyte monitoring device comprising a non-transitory memory and a processor, wherein the non-transitory memory is programmed with instructions that cause the processor to:receive control information, wherein the control information comprises a range of analyte concentration values for a control solution;determine the presence of the control solution by automatically identifying a fluid sample as the control solution, wherein the control solution has a known and/or predetermined concentration of at least one analyte;analyze the control solution to measure the concentration of the at least one analyte contained therein;compare the measured concentration of the at least one analyte with the control information; andprovide a signal to indicate whether the measured concentration falls within the range of concentration values.
  • 14. The system of claim 13 further comprising a control solution device containing the control solution therein.
  • 15. The system of claim 14 wherein the analyte monitoring device is configured to detect the presence of the control solution device.
  • 16. The system of claim 14 wherein the analyte monitoring device is configured to lance the control solution device to extract the control solution.
  • 17. The system of claim 13 wherein the instructions that cause the processor to determine the presence of the control solution comprise instructions that cause the processor to analyze the fluid sample using a colorimetric technique.
  • 18. The system of claim 13 wherein the instructions that cause the processor to determine the presence of the control solution comprise instructions that cause the processor to analyze the rate of reaction of the fluid sample.
  • 19. The system of claim 13 wherein the instructions that cause the processor to determine the presence of the control solution comprise instructions that cause the processor to analyze the wavelength of the fluid sample.
  • 20. The system of claim 13 wherein the at least one analyte comprises glucose.
  • 21. The system of claim 13 further comprising a test cartridge.
  • 22. The system of claim 21 wherein the test cartridge comprises a multi-test cartridge.
  • 23. The system of claim 21 wherein the control information is contained in a barcode or an RFID chip associated with the test cartridge.
  • 24. A method of verifying the accuracy of an analyte monitoring device through a control test, the method comprising: receiving control information with the analyte monitoring device, wherein the control information comprises a range of analyte concentration values for a control solution;receiving a fluid sample with the analyte monitoring device;identifying the fluid sample as the control solution by analyzing the wavelength of the fluid sample, wherein the control solution has a known and/or predetermined concentration of at least one analyte;analyzing the control solution to measure the concentration of the at least one analyte contained therein;comparing the measured concentration of the at least one analyte in the control solution with the control information; andproviding a signal to indicate whether the measured concentration falls within the range of analyte concentration values.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 14/557,327, filed on Dec. 1, 2014, issued as U.S. Pat. No. 9,897,610 on Feb. 20, 2018, which is a continuation of U.S. patent application Ser. No. 12/957,215, filed on Nov. 30, 2010, issued as U.S. Pat. No. 8,919,605 on Dec. 30, 2014, both of which are incorporated in their entireties by this reference. U.S. patent application Ser. No. 12/957,215 claims priority to U.S. Patent Application No. 61/358,791, filed Jun. 25, 2010, and U.S. Patent Application No. 61/265,247, filed Nov. 30, 2009.

US Referenced Citations (781)
Number Name Date Kind
842690 Oswalt Jan 1907 A
D137874 Partridge May 1944 S
2749797 Harks Mar 1950 A
3092465 Adams, Jr. Jun 1963 A
3310002 Wilburn Mar 1967 A
3620209 Kravitz Nov 1971 A
3623475 Sanz et al. Nov 1971 A
3626929 Sanz et al. Dec 1971 A
3630957 Rey Dec 1971 A
D223165 Komendat Mar 1972 S
3723064 Liotta Mar 1973 A
3741197 Sanz et al. Jun 1973 A
3961898 Neeley et al. Jun 1976 A
3992158 Przybylowicz et al. Nov 1976 A
4014328 Cluff et al. Mar 1977 A
4042335 Clement Aug 1977 A
4057394 Genshaw Nov 1977 A
4109655 Chacornac Aug 1978 A
4250257 Lee et al. Feb 1981 A
4253083 Imamura Feb 1981 A
4254083 Columbus Mar 1981 A
4258001 Pierce et al. Mar 1981 A
4260257 Neeley et al. Apr 1981 A
4289459 Neeley et al. Sep 1981 A
4311792 Avery Jan 1982 A
4321397 Nix et al. Mar 1982 A
4350762 DeLuca et al. Sep 1982 A
4394512 Batz Jul 1983 A
4414975 Ryder et al. Nov 1983 A
4416279 Lindner et al. Nov 1983 A
4418037 Katsuyama et al. Nov 1983 A
4422941 Vaughan, Jr. et al. Dec 1983 A
4429700 Thees et al. Feb 1984 A
4627445 Garcia et al. Dec 1986 A
4637403 Garcia et al. Jan 1987 A
4637406 Guinn et al. Jan 1987 A
4653513 Dombrowski Mar 1987 A
4661319 Lape Apr 1987 A
4702261 Cornell et al. Oct 1987 A
4711250 Gilbaugh, Jr. et al. Dec 1987 A
4737458 Batz et al. Apr 1988 A
4747687 Hoppe et al. May 1988 A
4749655 Monthony et al. Jun 1988 A
4767415 Duffy Aug 1988 A
4774192 Terminiello et al. Sep 1988 A
4787398 Garcia et al. Nov 1988 A
4790979 Terminiello et al. Dec 1988 A
4794926 Munsch et al. Jan 1989 A
4815843 Tiefenthaler et al. Mar 1989 A
4829470 Wang May 1989 A
4844095 Chiodo et al. Jul 1989 A
4846785 Cassou et al. Jul 1989 A
4887306 Hwang et al. Dec 1989 A
4920977 Haynes May 1990 A
4929426 Bodai et al. May 1990 A
4930525 Palestrant Jun 1990 A
4935346 Phillips Jun 1990 A
4953552 De Marzo Sep 1990 A
4966646 Zdeblick Oct 1990 A
4983178 Schnell Jan 1991 A
4995402 Smith Feb 1991 A
5029583 Meserol Jul 1991 A
5035704 Lambert et al. Jul 1991 A
5037199 Hlousek Aug 1991 A
5049487 Phillips et al. Sep 1991 A
5050617 Columbus et al. Sep 1991 A
5054878 Gergely et al. Oct 1991 A
5059394 Phillips et al. Oct 1991 A
5077199 Basagni et al. Dec 1991 A
5094943 Siedel et al. Mar 1992 A
5110724 Hewett May 1992 A
5114350 Hewett May 1992 A
5116759 Klainer et al. May 1992 A
5131404 Neeley et al. Jul 1992 A
5141868 Shanks et al. Aug 1992 A
5145565 Kater et al. Sep 1992 A
5146437 Boucheron Sep 1992 A
5153416 Neeley Oct 1992 A
5164575 Neeley et al. Nov 1992 A
5166498 Neeley Nov 1992 A
5174291 Schoonen et al. Dec 1992 A
5176632 Bernardi Jan 1993 A
5179005 Phillips et al. Jan 1993 A
5183741 Arai et al. Feb 1993 A
5194393 Hugl et al. Mar 1993 A
5196302 Kidwell Mar 1993 A
5208163 Charlton et al. May 1993 A
5213966 Vuorinen et al. May 1993 A
5217480 Habar et al. Jun 1993 A
5218966 Yamasawa Jun 1993 A
5223219 Subramanian et al. Jun 1993 A
5228972 Osaka et al. Jul 1993 A
5234818 Zimmermann et al. Aug 1993 A
5241969 Carson et al. Sep 1993 A
5251126 Kahn et al. Oct 1993 A
D341848 Bigelow et al. Nov 1993 S
5266266 Nason Nov 1993 A
5269800 Davis, Jr. Dec 1993 A
5275159 Griebel Jan 1994 A
5278079 Gubinski et al. Jan 1994 A
5279294 Anderson et al. Jan 1994 A
5288646 Lundsgaard et al. Feb 1994 A
5299571 Mastrototaro Apr 1994 A
5301686 Newman Apr 1994 A
5302513 Mike et al. Apr 1994 A
5304468 Phillips et al. Apr 1994 A
5306623 Kiser et al. Apr 1994 A
5308767 Terashima May 1994 A
5314441 Cusack et al. May 1994 A
5320607 Ishibashi Jun 1994 A
5354537 Moreno Oct 1994 A
5360595 Bell et al. Nov 1994 A
5368047 Suzuki et al. Nov 1994 A
5383512 Jarvis Jan 1995 A
5390671 Lord et al. Feb 1995 A
5395388 Schraga Mar 1995 A
5399316 Yamada Mar 1995 A
5401110 Neeley Mar 1995 A
5402798 Swierczek et al. Apr 1995 A
5426032 Phillips et al. Jun 1995 A
5441513 Roth Aug 1995 A
5451350 Macho et al. Sep 1995 A
5458140 Eppstein et al. Oct 1995 A
5460777 Kitajima et al. Oct 1995 A
5460968 Yoshida et al. Oct 1995 A
5482473 Lord et al. Jan 1996 A
5489414 Schreiber et al. Feb 1996 A
5506200 Hirschkoff et al. Apr 1996 A
5507288 Böcker et al. Apr 1996 A
5508200 Tiffany et al. Apr 1996 A
5510266 Bonner et al. Apr 1996 A
5514152 Smith May 1996 A
5518689 Dosmann et al. May 1996 A
5525518 Lundsgaard et al. Jun 1996 A
5527892 Borsotti et al. Jun 1996 A
5563042 Phillips et al. Oct 1996 A
5568806 Cheney, II et al. Oct 1996 A
5569287 Tezuka et al. Oct 1996 A
5575403 Charlton et al. Nov 1996 A
5577499 Teves Nov 1996 A
5582184 Erickson et al. Dec 1996 A
5586553 Halili et al. Dec 1996 A
5591139 Lin et al. Jan 1997 A
5593838 Zanzucchi et al. Jan 1997 A
5602647 Xu et al. Feb 1997 A
5611809 Marshall et al. Mar 1997 A
5611999 Dosmann et al. Mar 1997 A
5624458 Lipscher Apr 1997 A
5630986 Charlton et al. May 1997 A
5632410 Moulton et al. May 1997 A
5636632 Bommannan et al. Jun 1997 A
5638828 Lauks et al. Jun 1997 A
5647851 Pokras Jul 1997 A
5658515 Lee et al. Aug 1997 A
5660791 Brenneman et al. Aug 1997 A
5670031 Hintsche et al. Sep 1997 A
5676850 Reed et al. Oct 1997 A
5680858 Hansen et al. Oct 1997 A
5681484 Zanzucchi et al. Oct 1997 A
5682233 Brinda Oct 1997 A
5697901 Eriksson Dec 1997 A
5700695 Yassinzadeh et al. Dec 1997 A
5701181 Boiarski et al. Dec 1997 A
5701910 Powles et al. Dec 1997 A
D389761 Thomas Jan 1998 S
5705018 Hartley Jan 1998 A
5708247 McAleer Jan 1998 A
5708787 Nakano et al. Jan 1998 A
5715417 Gardien et al. Feb 1998 A
5730753 Morita Mar 1998 A
5735273 Kurnik et al. Apr 1998 A
5736103 Pugh Apr 1998 A
5741211 Renirie et al. Apr 1998 A
5746217 Erickson et al. May 1998 A
5746720 Stouder, Jr. May 1998 A
5753452 Smith May 1998 A
5757666 Schreiber et al. May 1998 A
5759364 Charlton et al. Jun 1998 A
5766066 Ranniger Jun 1998 A
5771890 Tamada Jun 1998 A
5789255 Yu Aug 1998 A
5797693 Jaeger Aug 1998 A
5800420 Gross et al. Sep 1998 A
5801057 Smart et al. Sep 1998 A
5807375 Gross et al. Sep 1998 A
5820570 Erickson et al. Oct 1998 A
5827183 Kurnik et al. Oct 1998 A
5840020 Heinonen et al. Nov 1998 A
5841126 Fossum et al. Nov 1998 A
5843692 Phillips et al. Dec 1998 A
5846837 Thym et al. Dec 1998 A
5851215 Mawhirt et al. Dec 1998 A
5854074 Charlton et al. Dec 1998 A
D403975 Douglas et al. Jan 1999 S
5855801 Lin et al. Jan 1999 A
5856195 Charlton et al. Jan 1999 A
5858194 Bell Jan 1999 A
5866281 Guckel et al. Feb 1999 A
5866349 Lilja et al. Feb 1999 A
5871494 Simons et al. Feb 1999 A
5879310 Sopp et al. Mar 1999 A
5879326 Godshall et al. Mar 1999 A
5879367 Latterell et al. Mar 1999 A
5885839 Lingane et al. Mar 1999 A
5891053 Sesekura Apr 1999 A
5893870 Talen et al. Apr 1999 A
D411621 Eisenbarth et al. Jun 1999 S
5911711 Pelkey Jun 1999 A
5911737 Lee et al. Jun 1999 A
5912139 Iwata et al. Jun 1999 A
5925021 Castellano et al. Jul 1999 A
5926271 Couderc et al. Jul 1999 A
5928207 Pisano et al. Jul 1999 A
5930873 Wyser Aug 1999 A
5938679 Freeman et al. Aug 1999 A
5945678 Yanagisawa Aug 1999 A
5951492 Douglas et al. Sep 1999 A
5951493 Douglas et al. Sep 1999 A
5951521 Mastrototaro et al. Sep 1999 A
5954685 Tierney Sep 1999 A
5962215 Douglas et al. Oct 1999 A
5968760 Phillips et al. Oct 1999 A
5968765 Grage et al. Oct 1999 A
5968836 Matzinger et al. Oct 1999 A
5971941 Simons et al. Oct 1999 A
5972294 Smith et al. Oct 1999 A
5986754 Harding Nov 1999 A
5989409 Kurnik et al. Nov 1999 A
5993189 Mueller et al. Nov 1999 A
D417504 Love et al. Dec 1999 S
6001067 Shults et al. Dec 1999 A
6005545 Nishida et al. Dec 1999 A
6010463 Lauks et al. Jan 2000 A
6010519 Mawhirt et al. Jan 2000 A
6014135 Fernandes Jan 2000 A
6014577 Henning et al. Jan 2000 A
6015969 Nathel et al. Jan 2000 A
6023629 Tamada Feb 2000 A
6027459 Shain et al. Feb 2000 A
6030827 Davis et al. Feb 2000 A
6032059 Henning et al. Feb 2000 A
6036924 Simons et al. Mar 2000 A
6041253 Kost et al. Mar 2000 A
6045753 Loewy et al. Apr 2000 A
6048352 Douglas et al. Apr 2000 A
6050988 Zuck Apr 2000 A
6056701 Duchon et al. May 2000 A
6056734 Jacobsen et al. May 2000 A
6058321 Swayze et al. May 2000 A
6059815 Lee et al. May 2000 A
6061128 Zweig et al. May 2000 A
6063039 Cunningham et al. May 2000 A
6071251 Cunningham et al. Jun 2000 A
6071294 Simons et al. Jun 2000 A
6077660 Wong et al. Jun 2000 A
6080116 Erickson et al. Jun 2000 A
6083196 Trautman et al. Jul 2000 A
6086544 Hibner et al. Jul 2000 A
6090790 Eriksson Jul 2000 A
6091975 Daddona et al. Jul 2000 A
6093156 Cunningham et al. Jul 2000 A
6097831 Wieck et al. Aug 2000 A
6099484 Douglas et al. Aug 2000 A
6100107 Lei et al. Aug 2000 A
6102933 Lee et al. Aug 2000 A
6103033 Say et al. Aug 2000 A
6103197 Werner Aug 2000 A
6106751 Talbot et al. Aug 2000 A
6118126 Zanzucchi Sep 2000 A
6120676 Heller et al. Sep 2000 A
6121050 Han Sep 2000 A
6123861 Santini, Jr. et al. Sep 2000 A
6126899 Woudenberg et al. Oct 2000 A
6132449 Lum et al. Oct 2000 A
6139562 Mauze et al. Oct 2000 A
6142939 Eppstein et al. Nov 2000 A
6152942 Brenneman et al. Nov 2000 A
6162639 Douglas Dec 2000 A
6172743 Kley et al. Jan 2001 B1
6175752 Say et al. Jan 2001 B1
6176865 Mauze et al. Jan 2001 B1
6183434 Eppstein et al. Feb 2001 B1
6183489 Douglas et al. Feb 2001 B1
6184990 Amirkhanian et al. Feb 2001 B1
6187210 Lebouiz et al. Feb 2001 B1
6192891 Gravel et al. Feb 2001 B1
6193873 Ohara et al. Feb 2001 B1
6197257 Raskas Mar 2001 B1
6200296 Dibiasi et al. Mar 2001 B1
6206841 Cunningham et al. Mar 2001 B1
6214626 Meller et al. Apr 2001 B1
6219574 Cormier et al. Apr 2001 B1
6228100 Schraga May 2001 B1
6230051 Cormier et al. May 2001 B1
6231531 Lum et al. May 2001 B1
6241862 McAleer et al. Jun 2001 B1
6242207 Douglas et al. Jun 2001 B1
6245215 Douglas et al. Jun 2001 B1
6246966 Perry Jun 2001 B1
6251083 Yum et al. Jun 2001 B1
6251260 Heller et al. Jun 2001 B1
6254586 Mann et al. Jul 2001 B1
6255061 Mori et al. Jul 2001 B1
6256533 Yuzhakov et al. Jul 2001 B1
6268162 Phillips et al. Jul 2001 B1
6271045 Douglas et al. Aug 2001 B1
6272364 Kurnik Aug 2001 B1
6283926 Cunningham et al. Sep 2001 B1
6289230 Chaiken et al. Sep 2001 B1
6298254 Tamada Oct 2001 B2
6299578 Kurnik et al. Oct 2001 B1
6299757 Feldman et al. Oct 2001 B1
6306104 Cunningham et al. Oct 2001 B1
6309351 Kurnik et al. Oct 2001 B1
D450711 Istvan et al. Nov 2001 S
6312612 Sherman et al. Nov 2001 B1
6312812 Sherman et al. Nov 2001 B1
6312888 Wong et al. Nov 2001 B1
6315738 Nishikawa et al. Nov 2001 B1
6322808 Trautman et al. Nov 2001 B1
6329161 Heller et al. Dec 2001 B1
6331266 Powell et al. Dec 2001 B1
6332871 Douglas et al. Dec 2001 B1
6334856 Allen et al. Jan 2002 B1
6350273 Minagawa et al. Feb 2002 B1
6352514 Douglas et al. Mar 2002 B1
6356776 Berner et al. Mar 2002 B1
6358265 Thorne, Jr. et al. Mar 2002 B1
6364890 Lum et al. Apr 2002 B1
6375626 Allen et al. Apr 2002 B1
6375627 Mauze et al. Apr 2002 B1
6379969 Mauze et al. Apr 2002 B1
6391005 Lum et al. May 2002 B1
6391645 Huang et al. May 2002 B1
6402704 McMorrow Jun 2002 B1
6409679 Pyo Jun 2002 B2
6428664 BhulLar et al. Aug 2002 B1
6449608 Morita et al. Sep 2002 B1
6455324 Douglas Sep 2002 B1
6493069 Nagashimada Dec 2002 B1
6500134 Cassone Dec 2002 B1
6520973 McGarry Feb 2003 B1
6530892 Kelly Mar 2003 B1
6537243 Henning et al. Mar 2003 B1
6540675 Aceti et al. Apr 2003 B2
6544193 Abreu Apr 2003 B2
6544475 Douglas et al. Apr 2003 B1
6549796 Sohrab Apr 2003 B2
6555061 Leong et al. Apr 2003 B1
6558624 Lemmon et al. May 2003 B1
6579690 Bonnecaze et al. Jun 2003 B1
6589260 Schmelzeisen-Redeker et al. Jul 2003 B1
6591124 Sherman et al. Jul 2003 B2
6591125 Buse et al. Jul 2003 B1
6602205 Erickson et al. Aug 2003 B1
6612111 Hodges et al. Sep 2003 B1
6616616 Fritz et al. Sep 2003 B2
6626874 Duchamp Sep 2003 B1
6656167 Numao et al. Dec 2003 B2
6662031 Khalil et al. Dec 2003 B1
6679852 Schmelzeisen-Redeker et al. Jan 2004 B1
6690467 Reel Feb 2004 B1
6706000 Perez et al. Mar 2004 B2
6706049 Moerman Mar 2004 B2
6706159 Moerman et al. Mar 2004 B2
6707554 Miltner et al. Mar 2004 B1
6740800 Cunningham May 2004 B1
6743635 Neel et al. Jun 2004 B2
6744502 Hoff et al. Jun 2004 B2
6748275 Lattner et al. Jun 2004 B2
6753187 Cizdziel et al. Jun 2004 B2
6766817 da Silva Jul 2004 B2
6775001 Friberg et al. Aug 2004 B2
6793633 Douglas et al. Sep 2004 B2
6830669 Miyazaki et al. Dec 2004 B2
6836678 Tu Dec 2004 B2
6837858 Cunningham et al. Jan 2005 B2
6847451 Pugh Jan 2005 B2
6849052 Uchigaki et al. Feb 2005 B2
6890421 Ohara et al. May 2005 B2
6896850 Subramanian et al. May 2005 B2
6903815 Uchiyama et al. Jun 2005 B2
6918404 Da Silva Jul 2005 B2
6919960 Hansen et al. Jul 2005 B2
6923764 Aceti et al. Aug 2005 B2
6936476 Anderson et al. Aug 2005 B1
D511214 Sasano et al. Nov 2005 S
6988996 Roe et al. Jan 2006 B2
7004928 Aceti et al. Feb 2006 B2
7011630 Desai et al. Mar 2006 B2
7025774 Freeman et al. Apr 2006 B2
D519868 Sasano et al. May 2006 S
7052652 Zanzucchi et al. May 2006 B2
7066586 Da Silva Jun 2006 B2
7066890 Lam et al. Jun 2006 B1
7141058 Briggs et al. Nov 2006 B2
7154592 Reynolds et al. Dec 2006 B2
7156809 Quy Jan 2007 B2
7163616 Vreeke et al. Jan 2007 B2
7183552 Russell Feb 2007 B2
7192061 Martin Mar 2007 B2
D540343 Cummins Apr 2007 S
7223365 Von Der Goltz May 2007 B2
7225008 Ward et al. May 2007 B1
7226461 Boecker et al. Jun 2007 B2
7229458 Boecker et al. Jun 2007 B2
7258673 Racchini et al. Aug 2007 B2
D551243 Young Sep 2007 S
7270970 Anderson et al. Sep 2007 B2
7297151 Boecker et al. Nov 2007 B2
7299081 Mace et al. Nov 2007 B2
7316700 Alden et al. Jan 2008 B2
7323141 Kirchhevel et al. Jan 2008 B2
7323315 Marfurt Jan 2008 B2
7341830 Horn et al. Mar 2008 B2
7343188 Sohrab Mar 2008 B2
7344507 Briggs et al. Mar 2008 B2
7377904 Conway et al. May 2008 B2
7379167 Mawhirt et al. May 2008 B2
7427377 Zanzucchi et al. Sep 2008 B2
7439033 Marfurt Oct 2008 B2
D580068 Shigesada et al. Nov 2008 S
D580558 Shigesada et al. Nov 2008 S
7501053 Karinka et al. Mar 2009 B2
7537571 Freeman et al. May 2009 B2
D599373 Kobayashi et al. Sep 2009 S
D601257 Berlinger Sep 2009 S
7582063 Wurster et al. Sep 2009 B2
7585278 Aceti et al. Sep 2009 B2
D601444 Jones et al. Oct 2009 S
D601578 Poulet et al. Oct 2009 S
7655019 LeVaughn et al. Feb 2010 B2
7682318 Alden et al. Mar 2010 B2
7713214 Freeman et al. May 2010 B2
7725149 Peyser et al. May 2010 B2
D622393 Gatrall et al. Aug 2010 S
7780631 Lum et al. Aug 2010 B2
7803123 Perez et al. Sep 2010 B2
7819822 Calasso et al. Oct 2010 B2
7841992 Freeman et al. Nov 2010 B2
7879058 Ikeda Feb 2011 B2
7883473 LeVaughn et al. Feb 2011 B2
7887494 Emery et al. Feb 2011 B2
7955492 Fujiwara et al. Jun 2011 B2
7964372 Marfurt Jun 2011 B2
D642191 Barnett et al. Jul 2011 S
7972861 Deng et al. Jul 2011 B2
7988644 Freeman et al. Aug 2011 B2
8012103 Escutia et al. Sep 2011 B2
8012104 Escutia et al. Sep 2011 B2
8105849 McDevitt et al. Jan 2012 B2
D654926 Lipman et al. Feb 2012 S
8173439 Petrich et al. May 2012 B2
8184273 Dosmann et al. May 2012 B2
8202231 Freeman et al. Jun 2012 B2
8231832 Zanzucchi et al. Jul 2012 B2
8251920 Vreeke et al. Aug 2012 B2
8262614 Freeman et al. Sep 2012 B2
8267870 Freeman et al. Sep 2012 B2
8280476 Jina Oct 2012 B2
8298255 Conway et al. Oct 2012 B2
8303518 Aceti et al. Nov 2012 B2
8360993 Escutia et al. Jan 2013 B2
8360994 Escutia et al. Jan 2013 B2
8372015 Escutia et al. Feb 2013 B2
8372016 Freeman et al. Feb 2013 B2
8376959 Deck Feb 2013 B2
8382681 Escutia et al. Feb 2013 B2
8391940 Matzinger et al. Mar 2013 B2
8419657 Roe Apr 2013 B2
D691174 Lipman et al. Oct 2013 S
8574168 Freeman et al. Nov 2013 B2
8574895 Freeman et al. Nov 2013 B2
8628721 Eisenhardt et al. Jan 2014 B2
8696880 Beer et al. Apr 2014 B2
8702624 Alden Apr 2014 B2
8795201 Escutia et al. Aug 2014 B2
8801631 Escutia et al. Aug 2014 B2
8919605 Lipman et al. Dec 2014 B2
8969097 Emery et al. Mar 2015 B2
9017356 Schraga et al. Apr 2015 B2
9034639 Freeman et al. May 2015 B2
9060723 Escutia et al. Jun 2015 B2
9060727 Saikley et al. Jun 2015 B2
9063102 Hoenes et al. Jun 2015 B2
9089678 Freeman et al. Jul 2015 B2
9095292 Zanzucchi et al. Aug 2015 B2
9095847 Porsch et al. Aug 2015 B2
9097679 List et al. Aug 2015 B2
9101302 Mace et al. Aug 2015 B2
9131886 Harttig et al. Sep 2015 B2
9138179 Hoenes et al. Sep 2015 B2
9149215 Werner et al. Oct 2015 B2
9173608 Kuhr et al. Nov 2015 B2
9179872 Roe et al. Nov 2015 B2
9186097 Frey et al. Nov 2015 B2
9186104 Kraemer et al. Nov 2015 B2
9186468 Freeman et al. Nov 2015 B2
9226704 Deck Jan 2016 B2
9301171 List et al. Apr 2016 B2
9314194 Deshmukh et al. Apr 2016 B2
9326718 Petrich et al. May 2016 B2
9332931 Chan May 2016 B2
9332932 Okuyama et al. May 2016 B2
9339612 Freeman et al. May 2016 B2
9351680 Boecker et al. May 2016 B2
9364172 Konya et al. Jun 2016 B2
9366636 Emery et al. Jun 2016 B2
9375169 Choi et al. Jun 2016 B2
9375177 Planman et al. Jun 2016 B2
9380963 Gofman et al. Jul 2016 B2
9380974 Litherland et al. Jul 2016 B2
9386944 Freeman et al. Jul 2016 B2
9392968 Schraga Jul 2016 B2
9439591 Frey et al. Sep 2016 B2
9463463 He et al. Oct 2016 B2
9480419 Weiss et al. Nov 2016 B2
9480420 Konya et al. Nov 2016 B2
9486164 Roe Nov 2016 B2
9488585 Emeric et al. Nov 2016 B2
9517027 Kan et al. Dec 2016 B2
9560993 Freeman Feb 2017 B2
9561000 Lum Feb 2017 B2
9573761 List Feb 2017 B2
9599552 Baldus et al. Mar 2017 B2
9603562 Aceti et al. Mar 2017 B2
9636051 Emery et al. May 2017 B2
9668687 Volkmuth et al. Jun 2017 B2
9671387 Thoes et al. Jun 2017 B2
9717452 Roe et al. Aug 2017 B2
9724021 Freeman et al. Aug 2017 B2
9730625 Krasnow et al. Aug 2017 B2
9782114 Reynolds et al. Oct 2017 B2
9795334 Freeman et al. Oct 2017 B2
9820684 Freeman et al. Nov 2017 B2
9833183 Escutia et al. Dec 2017 B2
9839384 Escutia et al. Dec 2017 B2
9877676 Konya et al. Jan 2018 B2
9880254 Richter et al. Jan 2018 B2
9883828 Haar et al. Feb 2018 B2
9897610 Lipman et al. Feb 2018 B2
9927386 Wang et al. Mar 2018 B2
9931478 Hirshberg et al. Apr 2018 B2
9939403 Richter et al. Apr 2018 B2
9939404 Richter et al. Apr 2018 B2
9943256 Varsavsky et al. Apr 2018 B2
9943259 Kuhr et al. Apr 2018 B2
9949679 Renlund Apr 2018 B2
9965587 Aykroyd et al. May 2018 B2
9968284 Vidalis et al. May 2018 B2
9974471 Kam et al. May 2018 B1
9983140 Dickopf May 2018 B2
9987427 Polsky et al. Jun 2018 B1
10034628 Freeman et al. Jul 2018 B2
10080517 Chen et al. Sep 2018 B2
10194838 Weiss et al. Feb 2019 B2
10226208 Emery et al. Mar 2019 B2
10278621 List May 2019 B2
10309905 Dickopf Jun 2019 B2
10327689 Krasnow et al. Jun 2019 B2
10330667 Lipman et al. Jun 2019 B2
10383556 Lipman et al. Aug 2019 B2
10429337 Malecha et al. Oct 2019 B2
10433780 Escutia et al. Oct 2019 B2
10441205 Litherland et al. Oct 2019 B2
10729386 Lipman et al. Aug 2020 B2
10772550 Aceti et al. Sep 2020 B2
20010001034 Douglas May 2001 A1
20010027277 Klitmose Oct 2001 A1
20010027328 Lum et al. Oct 2001 A1
20010053891 Ackley Dec 2001 A1
20020002326 Causey, III et al. Jan 2002 A1
20020002344 Douglas et al. Jan 2002 A1
20020004640 Conn et al. Jan 2002 A1
20020006355 Whitson Jan 2002 A1
20020016568 Lebel et al. Feb 2002 A1
20020020688 Sherman et al. Feb 2002 A1
20020022934 Vogel et al. Feb 2002 A1
20020023852 Mcivor et al. Feb 2002 A1
20020042594 Lum et al. Apr 2002 A1
20020045243 Laska et al. Apr 2002 A1
20020052618 Haar et al. May 2002 A1
20020059030 Otworth May 2002 A1
20020067481 Wolf et al. Jun 2002 A1
20020087056 Aceti et al. Jul 2002 A1
20020136667 Subramanian et al. Sep 2002 A1
20020137998 Smart et al. Sep 2002 A1
20020160520 Orloff et al. Oct 2002 A1
20020168290 Yuzhakov et al. Nov 2002 A1
20020169394 Eppstein et al. Nov 2002 A1
20020169411 Sherman et al. Nov 2002 A1
20020177761 Orloff et al. Nov 2002 A1
20020177764 Sohrab Nov 2002 A1
20020183102 Withers et al. Dec 2002 A1
20020188223 Perez et al. Dec 2002 A1
20020198444 Uchigaki et al. Dec 2002 A1
20030012693 Otillar et al. Jan 2003 A1
20030028087 Yuzhakov et al. Feb 2003 A1
20030028125 Yuzhakov et al. Feb 2003 A1
20030039587 Niermann Feb 2003 A1
20030060730 Perez Mar 2003 A1
20030062262 Mansouri Apr 2003 A1
20030083685 Freeman et al. May 2003 A1
20030083686 Freeman et al. May 2003 A1
20030105961 Zatloukal et al. Jun 2003 A1
20030116596 Terasawa Jun 2003 A1
20030135166 Gonnelli Jul 2003 A1
20030135333 Aceti Jul 2003 A1
20030143746 Sage Jul 2003 A1
20030153844 Smith et al. Aug 2003 A1
20030153900 Aceti et al. Aug 2003 A1
20030175987 Verdonk et al. Sep 2003 A1
20030206302 Pugh Nov 2003 A1
20030207441 Eyster et al. Nov 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030211619 Olson et al. Nov 2003 A1
20030212344 Yuzhakov et al. Nov 2003 A1
20030212345 McAllister et al. Nov 2003 A1
20030212347 Sohrab Nov 2003 A1
20030216628 Bortz et al. Nov 2003 A1
20040010207 Flaherty et al. Jan 2004 A1
20040030353 Schmelzeisen-redeker et al. Feb 2004 A1
20040039303 Wurster et al. Feb 2004 A1
20040049219 Briggs et al. Mar 2004 A1
20040059256 Perez Mar 2004 A1
20040072357 Stiene et al. Apr 2004 A1
20040073140 Douglas Apr 2004 A1
20040092842 Boecker et al. May 2004 A1
20040092995 Boecker et al. May 2004 A1
20040094432 Neel et al. May 2004 A1
20040096959 Stiene et al. May 2004 A1
20040097796 Berman et al. May 2004 A1
20040098009 Boecker et al. May 2004 A1
20040102803 Boecker et al. May 2004 A1
20040120848 Teodorczyk Jun 2004 A1
20040122339 Roe et al. Jun 2004 A1
20040132167 Rule et al. Jul 2004 A1
20040138588 Saikley et al. Jul 2004 A1
20040155084 Brown Aug 2004 A1
20040157339 Burke et al. Aug 2004 A1
20040178218 Schomakers et al. Sep 2004 A1
20040186394 Roe et al. Sep 2004 A1
20040191119 Zanzucchi et al. Sep 2004 A1
20040199409 Brown Oct 2004 A1
20040202576 Aceti et al. Oct 2004 A1
20040209755 Moore et al. Oct 2004 A1
20040230216 LeVaughn et al. Nov 2004 A1
20040232180 Badillo Nov 2004 A1
20040236251 Roe et al. Nov 2004 A1
20040238675 Banaszkiewicz et al. Dec 2004 A1
20040242982 Sakata et al. Dec 2004 A1
20040249253 Racchini et al. Dec 2004 A1
20040259180 Burke et al. Dec 2004 A1
20050004494 Perez et al. Jan 2005 A1
20050010134 Douglas et al. Jan 2005 A1
20050015020 LeVaughn et al. Jan 2005 A1
20050027182 Siddiqui et al. Feb 2005 A1
20050033340 Lipoma et al. Feb 2005 A1
20050038680 McMahon Feb 2005 A1
20050070819 Poux et al. Mar 2005 A1
20050096686 Allen May 2005 A1
20050106713 Phan et al. May 2005 A1
20050109386 Marshall May 2005 A1
20050153428 Matsumoto Jul 2005 A1
20050154410 Conway et al. Jul 2005 A1
20050159678 Taniike et al. Jul 2005 A1
20050176133 Miyashita et al. Aug 2005 A1
20050187532 Thurau et al. Aug 2005 A1
20050192492 Cho et al. Sep 2005 A1
20050202567 Zanzucchi et al. Sep 2005 A1
20050202733 Yoshimura et al. Sep 2005 A1
20050209518 Sage, Jr. et al. Sep 2005 A1
20050215872 Berner et al. Sep 2005 A1
20050215923 Wiegel Sep 2005 A1
20050234494 Conway et al. Oct 2005 A1
20050244981 Frey et al. Nov 2005 A1
20050245844 Mace et al. Nov 2005 A1
20050255001 Padmaabhan et al. Nov 2005 A1
20050277972 Wong et al. Dec 2005 A1
20060008389 Sacherer et al. Jan 2006 A1
20060036134 Tarassenko et al. Feb 2006 A1
20060052724 Roe Mar 2006 A1
20060064035 Wang et al. Mar 2006 A1
20060094985 Aceti et al. May 2006 A1
20060117616 Jones et al. Jun 2006 A1
20060122536 Haar et al. Jun 2006 A1
20060135873 Karo et al. Jun 2006 A1
20060155317 List Jul 2006 A1
20060161078 Schraga Jul 2006 A1
20060178600 Kennedy et al. Aug 2006 A1
20060189908 Kennedy Aug 2006 A1
20060200044 Freeman et al. Sep 2006 A1
20060204399 Freeman et al. Sep 2006 A1
20060224172 LeVaughn et al. Oct 2006 A1
20060229533 Hoenes et al. Oct 2006 A1
20060241517 Fowler et al. Oct 2006 A1
20060257993 Mcdevitt et al. Nov 2006 A1
20060259102 Slatkine Nov 2006 A1
20060264996 LeVaughn et al. Nov 2006 A1
20060281187 Emery et al. Dec 2006 A1
20070016104 Jansen et al. Jan 2007 A1
20070017824 Rippeth et al. Jan 2007 A1
20070078313 Emery et al. Apr 2007 A1
20070078358 Escutia et al. Apr 2007 A1
20070083131 Escutia et al. Apr 2007 A1
20070100255 Boecker et al. May 2007 A1
20070112281 Olson May 2007 A1
20070149863 Padmanabhan et al. Jun 2007 A1
20070179404 Escutia et al. Aug 2007 A1
20070179405 Emery et al. Aug 2007 A1
20070253531 Okuzawa et al. Nov 2007 A1
20070255181 Alvarez-icaza et al. Nov 2007 A1
20070255302 Koeppel et al. Nov 2007 A1
20070274869 Rannikko Nov 2007 A1
20080046831 Imai et al. Feb 2008 A1
20080077048 Escutia et al. Mar 2008 A1
20080135559 Byrd Jun 2008 A1
20080139910 Mastrototaro Jun 2008 A1
20080194934 Ray et al. Aug 2008 A1
20080255598 LeVaughn et al. Oct 2008 A1
20080269625 Halperin et al. Oct 2008 A1
20080274447 Mecklenburg Nov 2008 A1
20090018426 Markle et al. Jan 2009 A1
20090054810 Zanzucchi et al. Feb 2009 A1
20090156923 Power et al. Jun 2009 A1
20090194432 Deng Aug 2009 A1
20090292489 Burke et al. Nov 2009 A1
20090301899 Hodges et al. Dec 2009 A1
20100010374 Escutia et al. Jan 2010 A1
20100021947 Emery et al. Jan 2010 A1
20100021948 Lipman et al. Jan 2010 A1
20100095229 Dixon et al. Apr 2010 A1
20100152660 Mack et al. Jun 2010 A1
20100174211 Frey et al. Jul 2010 A1
20100185120 Sacherer et al. Jul 2010 A1
20100217155 Poux et al. Aug 2010 A1
20100249652 Rush et al. Sep 2010 A1
20100331650 Batman et al. Dec 2010 A1
20110098599 Emery et al. Apr 2011 A1
20110105872 Chickering et al. May 2011 A1
20110201909 Emery et al. Aug 2011 A1
20120166090 Lipman et al. Jun 2012 A1
20120296179 Zanzucchi et al. Nov 2012 A1
20130110516 Abulhaj et al. May 2013 A1
20130158430 Aceti et al. Jun 2013 A1
20130158432 Escutia et al. Jun 2013 A1
20130172698 Reynolds et al. Jul 2013 A1
20130274568 Escutia et al. Oct 2013 A1
20130274579 Richter et al. Oct 2013 A1
20140316301 Escutia et al. Oct 2014 A1
20140336480 Escutia et al. Nov 2014 A1
20140376762 Lipman et al. Dec 2014 A1
20150037898 Baldus et al. Feb 2015 A1
20150153351 Lipman et al. Jun 2015 A1
20150182157 Boriah et al. Jul 2015 A1
20150212006 Emery et al. Jul 2015 A1
20150268228 Schulat et al. Sep 2015 A1
20150335272 Natale et al. Nov 2015 A1
20160011178 Hoenes et al. Jan 2016 A1
20160038066 Escutia et al. Feb 2016 A1
20160256106 Krasnow et al. Sep 2016 A1
20160367178 Emery et al. Dec 2016 A1
20160374603 Shaanan et al. Dec 2016 A1
20170095188 Emery et al. Apr 2017 A1
20170319121 Aceti et al. Nov 2017 A1
20170354355 Emery et al. Dec 2017 A1
20180008178 Escutia et al. Jan 2018 A1
20180214059 Escutia et al. Aug 2018 A1
20180296143 Anderson et al. Oct 2018 A1
20180310865 Escutia et al. Nov 2018 A1
20180338713 Polsky et al. Nov 2018 A1
20190000365 Beyerlein et al. Jan 2019 A1
20190104976 Reynolds et al. Apr 2019 A1
20190175086 Yang Jun 2019 A1
20190209064 Emery et al. Jul 2019 A1
20190209820 Chickering, III et al. Jul 2019 A1
20190269358 Messerschmidt Sep 2019 A1
20190274607 Krasnow et al. Sep 2019 A1
20190391129 Lipman et al. Dec 2019 A1
20200214605 Lipman et al. Jul 2020 A1
20200237280 Escutia et al. Jul 2020 A1
Foreign Referenced Citations (229)
Number Date Country
2 201 530 Sep 1997 CA
2402115 Sep 2001 CA
2 513 465 Aug 2004 CA
197 05 091 Feb 1999 DE
199 22 413 Nov 2000 DE
103 02 501 Aug 2004 DE
0 103 426 Mar 1984 EP
0 256 806 Feb 1988 EP
0 160 708 Oct 1989 EP
0 356 418 Feb 1990 EP
0 396-016 Nov 1990 EP
0 396-016 Nov 1990 EP
0 397 424 Nov 1990 EP
0 520 443 Dec 1992 EP
0 255-338 Feb 1998 EP
0 849 584 Jun 1998 EP
0 877 250 Nov 1998 EP
1 037 048 Sep 2000 EP
1 060 768 Dec 2000 EP
1 118 856 Jul 2001 EP
1 266-607 Dec 2002 EP
1 266-607 Dec 2002 EP
1 369 688 Oct 2003 EP
1 369 688 Oct 2003 EP
1 360-934 Nov 2003 EP
1 360-934 Nov 2003 EP
1 486-766 Dec 2004 EP
1 486-766 Dec 2004 EP
1 529-489 May 2005 EP
1 529-489 May 2005 EP
1 769-735 Apr 2007 EP
1 787 584 May 2007 EP
1 987 766 Nov 2008 EP
2 015 067 Jan 2009 EP
61-290342 Dec 1986 JP
63-305841 Dec 1988 JP
1-318963 Dec 1989 JP
3-63570 Mar 1991 JP
03093189 Apr 1991 JP
7-67861 Mar 1995 JP
7-213925 Aug 1995 JP
9-168530 Jun 1997 JP
9-313465 Sep 1997 JP
9-266889 Oct 1997 JP
9-294737 Nov 1997 JP
10-024028 Jan 1998 JP
10-505258 May 1998 JP
10-508518 Aug 1998 JP
10-318970 Dec 1998 JP
11-056822 Mar 1999 JP
11-281779 Oct 1999 JP
2000-116629 Apr 2000 JP
2000-126161 May 2000 JP
2000-168754 Jun 2000 JP
2000-254111 Sep 2000 JP
2001-159618 Jun 2001 JP
2001-515203 Sep 2001 JP
2001-281242 Oct 2001 JP
2001-305096 Oct 2001 JP
2001-330581 Nov 2001 JP
2002-502045 Jan 2002 JP
2002-085384 Mar 2002 JP
2002-514453 May 2002 JP
2002-168862 Jun 2002 JP
2003-507719 Feb 2003 JP
2003-108679 Apr 2003 JP
2003-180417 Jul 2003 JP
2004-000598 Jan 2004 JP
2004-500948 Jan 2004 JP
2004-117339 Apr 2004 JP
2004-202256 Jul 2004 JP
2004-209266 Jul 2004 JP
2004-519302 Jul 2004 JP
2004-522500 Jul 2004 JP
2004-528936 Sep 2004 JP
2005-009238 Feb 2005 JP
2005-503538 Feb 2005 JP
2005-087613 Apr 2005 JP
2006-512969 Apr 2005 JP
3638958 Apr 2005 JP
2005-525149 Aug 2005 JP
2005-237938 Sep 2005 JP
2005-525846 Sep 2005 JP
2005-527254 Sep 2005 JP
2006-506185 Feb 2006 JP
2006-512974 Apr 2006 JP
2006-516723 Jul 2006 JP
2006-521555 Sep 2006 JP
2006-527013 Nov 2006 JP
2007-014381 Jan 2007 JP
2007-054407 Mar 2007 JP
2007-067698 Mar 2007 JP
2007-136198 Jun 2007 JP
2007-521031 Aug 2007 JP
2007-527287 Sep 2007 JP
2007-311196 Nov 2007 JP
2007-537804 Dec 2007 JP
2008-043741 Feb 2008 JP
2008-125813 Jun 2008 JP
2008-212324 Sep 2008 JP
2013-505747 Feb 2013 JP
100458978 May 2005 KR
WO-8605966 Oct 1986 WO
WO-8800812 Feb 1988 WO
WO-8807666 Oct 1988 WO
WO-9114212 Sep 1991 WO
WO-9413203 Jun 1994 WO
WO-9510223 Apr 1995 WO
WO-9510223 Apr 1995 WO
WO-9604857 Feb 1996 WO
WO-9607907 Mar 1996 WO
WO-9614026 May 1996 WO
WO-9625088 Aug 1996 WO
WO-9704707 Feb 1997 WO
WO-9715227 May 1997 WO
WO-9729847 Aug 1997 WO
WO-9730344 Aug 1997 WO
WO-9741421 Nov 1997 WO
WO-9742885 Nov 1997 WO
WO-9742888 Nov 1997 WO
WO-9743962 Nov 1997 WO
WO-9800193 Jan 1998 WO
WO-9831275 Jul 1998 WO
WO-9835225 Aug 1998 WO
WO-9912008 Mar 1999 WO
WO-9923492 May 1999 WO
WO-9944508 Sep 1999 WO
WO-9956954 Nov 1999 WO
WO-9958051 Nov 1999 WO
WO-9962576 Dec 1999 WO
WO-0009184 Feb 2000 WO
WO-0013573 Mar 2000 WO
WO-0014269 Mar 2000 WO
WO-0014535 Mar 2000 WO
WO-0018449 Apr 2000 WO
WO-0018449 Apr 2000 WO
WO 0019185 Apr 2000 WO
WO-0036400 Jun 2000 WO
WO-0042422 Jul 2000 WO
WO-0074763 Dec 2000 WO
WO-0074763 Dec 2000 WO
WO-0078208 Dec 2000 WO
WO-0113795 Mar 2001 WO
WO-0116575 Mar 2001 WO
WO-0152727 Jul 2001 WO
WO-0164105 Sep 2001 WO
WO-0164105 Sep 2001 WO
WO-0172220 Oct 2001 WO
WO-0180728 Nov 2001 WO
WO-0185233 Nov 2001 WO
WO-0185233 Nov 2001 WO
WO-0191634 Dec 2001 WO
WO-0191634 Dec 2001 WO
WO-0200101 Jan 2002 WO
WO-0200101 Jan 2002 WO
WO-0249507 Jun 2002 WO
WO-0249509 Jun 2002 WO
WO-0249509 Jun 2002 WO
WO-02078533 Oct 2002 WO
WO-02078533 Oct 2002 WO
WO-02082052 Oct 2002 WO
WO-02082052 Oct 2002 WO
WO-02093144 Nov 2002 WO
WO-02100251 Dec 2002 WO
WO-02100251 Dec 2002 WO
WO-02101359 Dec 2002 WO
WO-02101359 Dec 2002 WO
WO-03007819 Jan 2003 WO
WO-2003030984 Apr 2003 WO
WO-2003066128 Aug 2003 WO
WO-2003066128 Aug 2003 WO
WO-2003070099 Aug 2003 WO
WO-2003071940 Sep 2003 WO
WO-2003071940 Sep 2003 WO
WO-03088834 Oct 2003 WO
WO-2004045375 Jun 2004 WO
WO-2004045375 Jun 2004 WO
WO-2004062499 Jul 2004 WO
WO-2004062500 Jul 2004 WO
WO-2004062500 Jul 2004 WO
WO-2004064636 Aug 2004 WO
WO-2004085995 Oct 2004 WO
WO-2004085995 Oct 2004 WO
WO-2004091693 Oct 2004 WO
WO-2004091693 Oct 2004 WO
WO-2004105827 Dec 2004 WO
WO-2004105827 Dec 2004 WO
WO-2005006939 Jan 2005 WO
WO-2005006939 Jan 2005 WO
WO-2005009238 Feb 2005 WO
WO-2005013824 Feb 2005 WO
WO-2005018709 Mar 2005 WO
WO-2005018709 Mar 2005 WO
WO-2005018710 Mar 2005 WO
WO-2005018710 Mar 2005 WO
WO-2005054840 Jun 2005 WO
WO-2005084543 Sep 2005 WO
WO-2005084546 Sep 2005 WO
WO-2005084546 Sep 2005 WO
WO-2005085995 Sep 2005 WO
WO-2005112763 Dec 2005 WO
WO-2006031920 Mar 2006 WO
WO-2006138226 Dec 2006 WO
WO-2006138226 Dec 2006 WO
WO-2007041062 Apr 2007 WO
WO-2007041062 Apr 2007 WO
WO-2007041063 Apr 2007 WO
WO-2007041063 Apr 2007 WO
WO-2007041244 Apr 2007 WO
WO-2007041244 Apr 2007 WO
WO-2007041287 Apr 2007 WO
WO-2007041287 Apr 2007 WO
WO-2007041355 Apr 2007 WO
WO-2007041355 Apr 2007 WO
WO-2007054317 May 2007 WO
WO-2007108519 Sep 2007 WO
WO-2007112034 Oct 2007 WO
WO-2007112034 Oct 2007 WO
WO-2008027319 Mar 2008 WO
WO-2008027319 Mar 2008 WO
WO-2008062648 May 2008 WO
WO-2009145920 Dec 2009 WO
WO-2009148624 Dec 2009 WO
WO-2009148626 Dec 2009 WO
WO-2011065981 Jun 2011 WO
WO-2011162823 Dec 2011 WO
WO-2013020103 Feb 2013 WO
WO-2014205412 Dec 2014 WO
WO-2018191700 Oct 2018 WO
Non-Patent Literature Citations (174)
Entry
ADA Consensus Development Panel. (Jan.-Feb. 1987). “Consensus Statement on Self-Monitoring of Blood Glucose,” Diabetes Care 10(1):95-99.
ADA (Jan. 1994). “Self-Monitoring of Blood Glucose,” Consensus Statement Diabetes Care 17(1):81-86.
Anonymous. (Sep. 30, 1993). “The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus.” The New England Journal of Medicine 329(14):977-986.
Anonymous. (Jun. 23, 1998). “Taking the “Ouch” Out of Needles: Arrays of “Microneedles” Offer New Techniques for Drug Delivery,” Science Daily, located at <http:www.sciencedaily.com/releases/1998/06/980623045850.htm>, last visited Jan. 14, 2014, 3 pages.
Beregszàszi, M. et al. (Jul. 1997). “Nocturnal Hypoglycemia in Children and Adolescents with Insulin-Dependent Diabetes Mellitus: Prevalence and Risk Factors,” J. Pediatrics 131(1 Pt. 1):27-33.
Brazzle, J. et al. Active Microneedles with Integrated Functionality, Solid-State Sensor and Actuator Workshop, Hilton Head Island, South Carolina, Jun. 4-8, 2000, Technical Digest, 199-202.
Burge, M.R., (Aug. 2001). “Lack of Compliance with Home Blood Glucose Monitoring Predicts Hospitalization in Diabetes”, Diabetes Care 24(8): 1502-1503.
Chase, H.P. et al. (Feb. 2001). “Continuous Subcutaneous Glucose Monitoring in Children with Type 1 Diabetes,” Pediatrics 107(2):222-226.
Clarke, W.L. et al. (Sep.-Oct. 1987). “Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose,” Diabetes Care 10(5):622-628.
Clarke, W.L. et al. (1981). “Evaluation of a New Reflectance Photometer for Use in Home Blood Glucose Monitoring,” Diabetes Care 4(5):547-550.
Collison, M.E. et al. (Sep. 1999). “Analytical Characterization of Electrochemical Biosensor Test Strips for Measurement of Glucose in Low-Volume Interstitial Fluid Samples,” Clinical Chemistry 45(9):1665-1673.
Coster, S. et al. (2000). “Monitoring Blood Glucose Control in Diabetes Mellitus: A Systematic Review.” Health Technology Assessment 4(12):1-93.
Cox, D.J. et al. (Jun. 1997). “Understanding Error Grid Analysis,” Diabetes Care 20(6):911-912.
D'Arrigo, T.D. (Mar. 2000). “GlucoWatch Monitor Poised for Approval,” Diabetes Forecast, 53(3):43-44.
Extended European Search Report dated Nov. 21, 2016, for EP Application No. 16 172 370.5, filed on Nov. 30, 2010, 9 pages.
Extended European Search Report dated Dec. 17, 2014, for EP Application No. 10 833 694.2, filed on Nov. 30, 2010, 11 pages.
Extended European Search Report dated Feb. 22, 2012, for EP Application No. EP 10 181 155.2, filed Sep. 28, 2010, 6 pages.
Extended European Search Report dated Nov. 8, 2016, for EP Application No. 16 167 087.2, filed on Aug. 3, 2012, 7 pages.
Extended European Search Report dated Apr. 19, 2011, for EP Application No. 10 18 0848.3 filed Sep. 28, 2010, 5 pages.
Extended European Search Report dated Jan. 22, 2013, for EP Application No. 12182900.6, filed on Sep. 29, 2006, 6 pages.
Extended European Search Report dated Apr. 29, 2013 for EP Patent Application No. 12192620.8, filed on Nov. 14, 2012, 8 pages.
Extended European Search Report dated Jul. 18, 2013, for EP Application No. 06 772 943.4, filed on Jun. 13, 2006, 7 pages.
Extended European Search Report dated Feb. 2, 2016 for European Patent Application No. 15187274.4, filed on Sep. 29, 2015, 6 pages.
Feldman, B. et al. (2000). “FreeStyleTM: A Small-Volume Electrochemical Glucose Sensor for Home Blood Glucose Testing,” Diabetes Technology and Therapeutics, 2(2):221-229.
Final Office Action dated May 9, 2014, for U.S. Appl. No. 12/957,215, filed Nov. 30, 2010, 20 pages.
Final Office Action dated Jul. 9, 2008, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 19 pages.
Final Office Action dated Nov. 23, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 20 pages.
Final Office Action dated Jan. 21, 2011, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 7 pages.
Final Office Action dated Aug. 15, 2013 for U.S. Appl. No. 13/562,129, filed Jul. 30, 2012, 12 pages.
Final Office Action dated Apr. 13, 2016, for U.S. Appl. No. 13/669,366, filed Nov. 5, 2012, 31 pages.
Final Office Action dated Aug. 28, 2014, for U.S. Appl. No. 13/562,129, filed Jul. 30, 2012, 11 pages.
Final Office Action dated Dec. 26, 2014, for U.S. Appl. No. 13/669,366, filed Nov. 5, 2012, 9 pages.
Final Office Action dated Jan. 22, 2014, for U.S. Appl. No. 13/669,366, filed Nov. 5, 2012, 8 pages.
Final Office Action dated Jun. 30, 2010, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 11 pages.
Final Office Action dated May 30, 2007, for U.S. Appl. No. 11/125,107, filed May 10, 2005, 11 pages.
Final Office Action dated Nov. 1, 2010, for U.S. Appl. No. 11/311,667, filed Dec. 20, 2005, 9 pages.
Final Office Action dated Nov. 21, 2011, for U.S. Appl. No. 11/311,667, filed Dec. 20, 2005, 8 pages.
Final Office Action dated Jun. 11, 2010, for U.S. Appl. No. 11/529,614, filed Sep. 29, 2006, 16 pages.
Final Office Action dated Mar. 10, 2015, for U.S. Appl. No. 11/529,614, filed Sep. 29, 2006, 24 pages.
Final Office Action dated Oct. 15, 2009, for U.S. Appl. No. 11/239,122, filed Sep. 30, 2005, 13 pages.
Final Office Action dated Aug. 14, 2012, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 14 pages.
Final Office Action dated Sep. 23, 2013, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 14 pages.
Final Office Action dated Mar. 5, 2009, for U.S. Appl. No. 11/239,123, filed Sep. 30, 2005, 17 pages.
Final Office Action dated Mar. 3, 2011, for U.S. Appl. No. 11/239,123, filed Sep. 30, 2005, 25 pages.
Final Office Action dated Jan. 6, 2016, for U.S. Appl. No. 14/321,631, filed Jul. 1, 2014, 9 pages.
Hemmerich, K.J. et al. (Apr. 1995).“Guide to Engineering Thermoplastics,” Medical Devices and Diagnostic Industry pp. 39-59.
Integ. (2000). “LifeGuide™ Glucose Meter. No Lancets. No Blood,” located at <http://www.integonline.com>, last visited May 1, 2000, 10 pages.
International Search Report dated Jan. 28, 2011, for PCT Application No. PCT/US2010/003063, filed on Nov. 30, 2010, 1 page.
International Search Report dated Dec. 3, 2004, for PCT Application No. PCT/US2004/08798, filed on Mar. 24, 2004, 3 pages.
International Search Report dated May 2, 2007, for PCT Application No. PCT/US2006/37923, filed on Sep. 9, 2006, 1 page.
International Search Report dated Aug. 16, 2007 for PCT Application No. PCT/US2006/038163, filed on Sep. 29, 2006, 1 page.
International Search Report dated Aug. 17, 2007 for PCT/US2006/38049, filed on Sep. 29, 2006, 1 page.
International Search Report dated Oct. 19, 2012 for PCT Application No. PCT/US2012/049629, filed on Aug. 3, 2012, 4 pages.
International Search Report dated Jan. 16, 2008, for PCT Application No. PCT/US2006/022840, filed on Jun. 13, 2006, 1 page.
International Search Report dated Aug. 20, 2007 for PCT Application No. PCT/US2006/37245, filed on Sep. 26, 2006, 1 page.
Ishii H. et al., (Aug. 2001). “Seasonal Variation of Glycemic Control in Type 2 Diabetic Patients”, Diabetes Care 24(8): 1503.
Johnson, R.N. et al. (Jan. 1998). “Accuracy of Devices Used for Self-Monitoring of Blood Glucose,” Annals of Clinical Biochemistry 35(1):68-74.
Johnson, R.N. et al. (Jan. 1999). “Analytical Error of Home Glucose Monitors: A Comparison of 18 Systems,” Annals of Clinical Biochemistry 36(1):72-79.
Johnson, R.N. et al.(2001). “Error Detection and Measurement in Glucose Monitors,” Clinica Chimica Acta 307:61-67.
Kumetrix, Inc. (Dec. 1999). “Painless Blood Glucose Monitoring, Courtesy of the Mosquito,” Start-Up pp. 27-28.
Lee, S-C.(Jun. 1999). “Light Scattering by Closely Spaced Parallel Cylinders Embedded in a Finite Dielectric Slab,” Journal of the Optical Society of America A 16(6):1350-1361.
Mahler, R.J. et al. (1999). “Clinical Review 102, Type 2 Diabetes Melitus: Update on Diagnosis Pathophysiology, and Treatment,” The Journal of Clinical Endocrinology and Metabolism 84(4):1165-1171.
Massey V. et al. (Aug. 1960). “Studies on the Reaction Mechanism of Lipoyl Dehydrogenase” Biochim. Biophys. Acta 48: 33-47.
Mcgarraugh, G. et al. (2001). “Physiological Influences on Off-Finger Glucose Testing,” Diabetes Technology & Therapeutics 3(3):367-376.
Mcnichols, R.J. et al. (Jan. 2000). “Optical Glucose Sensing in Biological Fluids: An Overview,” Journal of Biomedical Optics, 5(1):5-16.
Medline Plus. (Jun. 17, 2008). , Medical Encyclopedia, Monitor Blood Glucose-Series: Part 1-4, 6 pages.
Neeley, W.E. et al. (1981). “An Instrument for Digital Matrix Photometry,” Clinical Chemistry 27(10):1665-1668.
Neeley, W.E. (1983). “Reflectance Digital Matrix Photometry,” Clinical Chemistry 29(6):1038-1041.
Neeley, W.E. (1983). “Multilayer Film Analysis for Glucose in 1-□L Samples of Plasma,” Clinical Chemistry 29(12):2103-2105.
Neeley, W.E. (1988). “A Reflectance Photometer with a Square Photodiode Array Detector for Use on Multilayer Dry-Film Slides,” Clinical Chemistry 34(11):2367-2370.
Non-Final Office Action dated Sep. 24, 2013, for U.S. Appl. No. 12/957,215, filed Nov. 30, 2010, 16 pages.
Non-Final Office Action dated Dec. 12, 2007, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 13 pages.
Non-Final Office Action dated Apr. 28, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 21 pages.
Non-Final Office Action dated Jun. 4, 2010, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 23 pages.
Non-Final Office Action dated Mar. 23, 2012, for U.S. Appl. No. 13/197,592, filed Aug. 3, 2011, 7 pages.
Non-Final Office Action dated Mar. 23, 2012, for U.S. Appl. No. 13/197,603, filed Aug. 3, 2011, 6 pages.
Non-Final Office Action dated Nov. 26, 2012 for U.S. Appl. No. 13/562,129, filed Jul. 30, 2012, 9 pages.
Non Final Office Action dated Apr. 8, 2015, for U.S. Appl. No. 13/566,886, filed Aug. 3, 2012, 11 pages.
Non-Final Office Action dated Mar. 19, 2009, for U.S. Appl. No. 11/239,122, filed Sep. 30, 2005, 15 pages.
Non-Final Office Action dated Sep. 1, 2010, for U.S. Appl. No. 11/239,122, filed Sep. 30, 2005, 15 pages.
Non Final Office Action dated Apr. 12, 2011, for U.S. Appl. No. 11/311,667, filed Dec. 20, 2005, 7 pages.
Non Final Office Action dated Aug. 5, 2014, for U.S. Appl. No. 13/669,366, filed Nov. 5, 2012, 8 pages.
Non Final Office Action dated Dec. 5, 2014, for U.S. Appl. No. 13/562,129, filed Jul. 30, 2012, 7 pages.
Non Final Office Action dated Jan. 12, 2009, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 9 pages.
Non Final Office Action dated Jan. 21, 2011, for U.S. Appl No. 11/529,612, filed Sep. 29, 2006, 9 pages.
Non Final Office Action dated Jul. 13, 2010, for U.S. Appl. No. 12/222,724, filed Aug. 14, 2008, 11 pages.
Non Final Office Action dated Jul. 31, 2015, for U.S. Appl. No. 13/669,366, filed Nov. 5, 2012, 16 pages.
Non Final Office Action dated Mar. 21, 2014, for U.S. Appl. No. 13/562,129, filed Jul. 30, 2012, 12 pages.
Non Final Office Action dated Mar. 25, 2011, for U.S. Appl. No. 12/222,724, filed Aug. 14, 2008, 13 pages.
Non Final Office Action dated Mar. 5, 2010, for U.S. Appl. No. 11/311,667, filed Dec. 20, 2005, 8 pages.
Non Final Office Action dated May 14, 2008, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 9 pages.
Non Final Office Action dated May 16, 2013, for U.S. Appl. No. 13/669,366, filed Nov. 5, 2012, 8 pages.
Non Final Office Action dated May 5, 2005, for U.S. Appl. No. 10/131,268, filed Apr. 23, 2002, 8 pages.
Non Final Office Action dated Nov. 2, 2006, for U.S. Appl. No. 11/125,107, filed May 10, 2005, 10 pages.
Non Final Office Action dated Oct. 14, 2009, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 10 pages.
Non Final Office Action dated Oct. 3, 2008, for U.S. Appl. No. 10/722,074, filed Nov. 24, 2003, 10 pages.
Non-Final Office Action dated Dec. 17, 2015, for U.S. Appl. No. 11/529,614, filed Sep. 29, 2006, 6 pages.
Non Final Office Action dated Dec. 2, 2004, for U.S. Appl. No. 10/347,620, filed Jan. 22, 2003, 8 pages.
Non-Final Office Action dated Jan. 27, 2009, for U.S. Appl. No. 11/529,614, filed Sep. 29, 2006, 17 pages.
Non-Final Office Action dated Jan. 6, 2014, for U.S. Appl. No. 11/529,614, filed Sep. 29, 2006, 12 pages.
Non-Final Office Action dated Jun. 21, 2013, for U.S. Appl. No. 13/752,261, filed Jan. 28, 2013, 12 pages.
Non-Final Office Action dated Jun. 6, 2008, for U.S. Appl. No. 11/529,614, filed Sep. 29, 2006, 17 pages.
Non-Final Office Action dated Oct. 9, 2014, for U.S. Appl. No. 14/446,262, filed Jul. 29, 2014, 15 pages.
Non Final Office Action dated Sep. 29, 2004, for U.S. Appl. No. 10/394,230, filed Mar. 24, 2003, 10 pages.
Non-Final Office Action dated Sep. 13, 2011, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 14 pages.
Non-Final Office Action dated Feb. 28, 2013, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 12 pages.
Non-Final Office Action dated Apr. 10, 2014, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 14 pages.
Non-Final Office Action dated May 29, 2015, for U.S. Appl. No. 14/614,177, filed Feb. 4, 2015, 13 pages.
Non-Final Office Action dated Nov. 1, 2007, for U.S. Appl. No. 11/239,123, filed Sep. 30, 2005, 15 pages.
Non-Final Office Action dated Apr. 15, 2010, for U.S. Appl. No. 11/239,123, filed Sep. 30, 2005, 19 pages.
Non-Final Office Action dated Sep. 19, 2013, for U.S. Appl. No. 11/239,123, filed Sep. 30, 2005, 24 pages.
Non-Final Office Action dated Aug. 8, 2014, for U.S. Appl. No. 14/321,631, filed Jul. 1, 2014, 11 pages.
Notice of Allowance dated Apr. 3, 2014, for U.S. Appl. No. 11/239,123, filed Sep. 30, 2005, 6 pages.
Notice of Allowance dated Apr. 18, 2012, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 8 pages.
Notice of Allowance dated Apr. 19, 2010, for U.S. Appl. No. 29/338,117, filed Jun. 4, 2009, 4 pages.
Notice of Allowance dated Aug. 3, 2012, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 5 pages.
Notice of Allowance dated Jan. 14, 2010, for U.S. Appl. No. 29/338,117, filed Jun. 4, 2009, 4 pages.
Notice of Allowance dated Jun. 29, 2012, for U.S. Appl. No. 11/311,667, filed Dec. 20, 2005, 5 pages.
Notice of Allowance dated Mar. 14, 2012, for U.S. Appl. No. 12/222,724, filed Aug. 14, 2008, 7 pages.
Notice of Allowance dated Mar. 31, 2005, for U.S. Appl. No. 10/394,230, filed Mar. 24, 2003, 10 pages.
Notice of Allowance dated May 15, 2008, for U.S. Appl. No. 11/125,107, filed May 10, 2005, 7 pages.
Notice of Allowance dated May 28, 2009, for U.S. Appl. No. 29/300,933, filed May 30, 2008, 6 pages.
Notice of Allowance dated Nov. 23, 2011, for U.S. Appl. No. 12/222,724, filed Aug. 14, 2008, 7 pages.
Notice of Allowance dated Nov. 27, 2012, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 5 pages.
Notice of Allowance dated Nov. 29, 2005, for U.S. Appl. No. 10/131,268, filed Apr. 23, 2002, 6 pages.
Notice of Allowance dated Oct. 12, 2011, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 8 pages.
Notice of Allowance dated May 3, 2011, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 12 pages.
Notice of Allowance dated Mar. 27, 2015, for U.S. Appl. No. 13/562,129, filed Jul. 30, 2012, 7 pages.
Notice of Allowance dated Aug. 19, 2014, for U.S. Appl. No. 12/957,215, filed Nov. 30, 2010, 9 pages.
Notice of Allowance dated Feb. 23, 2015, for U.S. Appl. No. 14/446,262, filed Jul. 29, 2014, 8 pages.
Notice of Allowance dated Feb. 5, 2014, for U.S. Appl. No. 13/752,261, filed Jan. 28, 2013, 9 pages.
Notice of Allowance dated Jun. 15, 2009, for U.S. Appl. No. 10/722,074, filed Nov. 24, 2003, 6 pages.
Notice of Allowance dated Mar. 2, 2016, for U.S. Appl. No. 11/529,614, filed Sep. 29, 2006, 12 pages.
Notice of Allowance dated Mar. 28, 2005, for U.S. Appl. No. 10/347,620, filed Jan. 22, 2003, 6 pages.
Notice of Allowance dated Sep. 18, 2014, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 9 pages.
Notice of Allowance dated Feb. 16, 2016, for U.S. Appl. No. 14/614,177, filed Feb. 4, 2015, 7 pages.
Otto, E. et al. (2000). “An Intelligent Diabetes Software Prototype: Predicting Blood Glucose Levels and Recommending Regimen Changes,” Diabetes Technology and Therapeutics 2(4):569-576.
Pfohl, M. et al. (2000). “Spot Glucose Measurement in Epidermal Interstitial Fluid—An Alternative to Capillary Blood Glucose Estimation,” Experimental and Clinical Endocrinology & Diabetes 108(1):1-4.
Princen, H.M. (May 1969). “Capillary Phenomena in Assemblies of Parallel Cylinders, I. Capillary Rise Between Two Cylinders,” Journal of Colloid and Interface Science 30(1):69-75.
Princen, H.M. (Jul. 1969). “Capillary Phenomena in Assemblies of Parallel Cylinders, II. Capillary Rise in Systems with More Than Two Cylinders,” Journal of Colloid and Interface Science 30(3):359-371.
Rebrin, K. et al. (Sep. 1999). “Subcutaneous Glucose Predicts Plasma Glucose Independent of Insulin: Implications for Continuous Monitoring,” American Journal of Physiology 277(3):E561-E571.
Rosen, S. (1999). “Road to New-Age Glucose Monitoring Still Rocky,” Diagnostic Insight, pp. 4-5, 12-13, 16.
Smart, W.H. et al. (2000). “The Use of Silicon Microfabrication Technology in Painless Glucose Monitoring,” Diabetes Technology & Therapeutics 2(4):549-559.
Spielman, A. et al.(2001). Mosquito: A Natural History of Our Most Persistent and Deadly Foe, First Edition, Hyperion, New York, NY, 3 pages. (Table of Contents Only).
Sonntag, O. (1993). Ektachem. Dry Chemistry, Analysis With Carrier-Bound Reagents, Elsevier Science Publishers, 57 pages.
Straub F.B. (Mar. 1939). “Isolation and Properties of a flavoprotien from Heart Muscle Tissue”, Biochemical Journal 33: 787-792.
Svedman, C. et al. (Apr. 1999). “Skin Mini-Erosion Technique for Monitoring Metabolites in Interstitial Fluid: Its Feasibility Demonstrated by OGTT Results in Diabetic and Non-Diabetic Subjects,” Scand. J. Clin. Lab. Invest. 59(2):115-123.
Tietz, N.W. (1986). Textbook of Clinical Chemistry, W.B. Saunders Company, pp. 1533 and 1556.
Trinder, P. (1969). “Determination of Glucose in Blood Using Glucose Oxidase with an Alternate Oxygen Acceptor,” Annals of Clinical Biochemistry 6:24-28.
U.S. Precision Lens, Inc. (1983).The Handbook of Plastic Optics.
Wikipedia (2016). “Capillary action,” 7 pages.
Written Opinion dated Jan. 28, 2011, for PCT Application No. PCT/US2010/003063, filed on Nov. 30, 2010, 6 pages.
Written Opinion dated Dec. 3, 2004, for PCT Application No. PCT/US2004/08798, filed on Mar. 24, 2004, 4 pages.
Written Opinion dated May 2, 2007, for PCT Application No. PCT/US2006/37923, filed on Sep. 9, 2006, 5 pages.
Written Opinion dated Aug. 17, 2007 for PCT/US2006/38049, filed on Sep. 29, 2006, 6 pages.
Written Opinion dated Aug. 20, 2007 for PCT Application No. PCT/US2006/37245, filed on Sep. 26, 2006, 7 pages.
Written Opinion dated Aug. 16, 2007 for PCT Application No. PCT/US2006/038163, filed on Sep. 29, 2006, 4 pages.
Written Opinion dated Oct. 19, 2012 for PCT Application No. PCT/US2012/049629, filed on Aug. 3, 2012, 7 pages.
Written Opinion of the International Searching Authority dated Jan. 16, 2008, for PCT Application No. PCT/US2006/022840, filed on Jun. 13, 2006, 3 pages.
Yum, S. I. et al. (Nov. 1, 1999). “Capillary Blood Sampling for Self-Monitoring of Blood Glucose,” Diabetes Technology & Therapeutics, 1(1):29-37.
Office Action dated Apr. 17, 2017, by The United States Patent and Trademark Office for U.S. Appl. No. 14/557,327, 12 pages.
Extended European Search Report dated Nov. 8, 2016 from the European Patent Office for Application No. 16167087.2, filed Aug. 3, 2012, 6 pages.
Non-Final Office Action dated Dec. 16, 2016, for U.S. Appl. No. 13/566,886, filed Aug. 3, 2012, 11 pages.
Non-Final Office Action dated Mar. 20, 2017, by The United States Patent and Trademark Office for U.S. Appl. No. 15/191,434, filed Jun. 23, 2016, 20 pages.
Non-Final Office Action dated Mar. 21, 2017, for U.S. Appl. No. 15/177,041, filed Jun. 8, 2016, 11 pages.
Non-Final Office Action dated Jun. 20, 2017, for U.S. Appl. No. 15/191,434, filed Jun. 23, 2016, 20 pages.
Notice of Allowance dated Aug. 18, 2017, for U.S. Appl. No. 13/566,886, filed Aug. 3, 2012, 10 pages.
Notice of Allowance dated Oct. 19, 2017, by The United States Patent and Trademark Office for U.S. Appl. No. 14/557,327, 10 pages.
Final Office Action dated Nov. 29, 2017, for U.S. Appl. No. 15/177,041, filed Jun. 8, 2016, 13 pages.
Notice of Allowance dated Jul. 20, 2018, for U.S. Appl. No. 15/177,041, filed Jun. 8, 2016, 11 pages.
Non-Final Office Action dated Aug. 15, 2018, for U.S. Appl. No. 15/191,434, filed Jun. 23, 2016, 19 pages.
Khalil, “Non-invasive glucose measurement technologies: an update from 1999 to the dawn of the new millennium,” Diabetes Technology & Therapeutics., vol. 6, No. 5, 2004.
Non-Final Office Action dated Apr. 20, 2020, for U.S. Appl. No. 16/159,546, filed Oct. 12, 2018, 8 pages.
Non-Final Office Action dated Aug. 7, 2020, for U.S. Appl. No. 15/697,311, filed Sep. 6, 2017, 10 pages.
Related Publications (1)
Number Date Country
20190025318 A1 Jan 2019 US
Provisional Applications (2)
Number Date Country
61358791 Jun 2010 US
61265247 Nov 2009 US
Continuations (2)
Number Date Country
Parent 14557327 Dec 2014 US
Child 15895830 US
Parent 12957215 Nov 2010 US
Child 14557327 US